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Abstract 
The estrogen-related receptor alpha (ERRα) is an orphan nuclear receptor (NR) 
with no natural ligand identified. Recent studies report that ERRα expression and 
activity correlate with poor prognosis in breast cancer. It is also suggested that ERRα is 
involved in tumor growth and progression, thus this receptor may be a therapeutic 
target in the treatment of breast cancer. However, the specific role of ERRα in breast 
cancer is not fully understood. Similar to other nuclear receptors, ERR has been 
suggested to regulate target gene transcription through both classical (direct DNA 
binding) and non-canonical (tethering to other transcription factors) to effect various 
aspects of tumor pathogenesis, such as angiogenesis, regulation of hypoxic response, 
tumor growth, and migration. Thus, the objective of this dissertation research is to 
explore the roles of ERRα in breast cancer by (a) identifying novel ERRα target genes 
important for tumor pathogenesis, (b) characterizing the molecular mechanism of non-
canonical actions of ERRα-mediated gene transcription, and (c) examining the structure 
basis of ERRα antagonism for future pharmaceutical exploitation. First, we identified an 
ERRα target gene, ECM1, which is relevant to breast cancer angiogenesis. The role of 
ECM1 in angiogenesis was confirmed by endothelial tube formation assay. We further 
showed that knocking down ECM1 has a dramatic inhibitory effect on tumor xenograft 
growth. This result, for the first time, directly demonstrates the role of ECM1 in tumor 
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environment and further sheds light on the significance of ERRα-regulated genes in 
tumors angiogenesis. Next, we explored the non-canonical pathways regulated by ERRα 
with a focus on the gene targets of ERRα and hypoxia inducible factor (HIF-1) pathways. 
It’s been demonstrated previously that ERRα affect some HIF-1 target gene through a 
tethering mechanism.  Using a candidate gene approach, we discovered that the 
expression of carbonic anhydrase 9 (CA9), an important regulator of pH balance in 
tumor microenvironment is a target gene co-regulated by ERRα and HIF-1.  However, it 
remains to be determined whether ERRα regulates CA9 through canonical, non-
canonical, indirect mechanisms, or some combinations of these.   To further dissect the 
mechanism by which ERRα and HIF-1 cross talk, we used simply reporter gene assay 
and determined that even in the absence of a discernible ERR responsive element 
(ERRE) an intact ERR DNA binding domain is indispensible. Finally, to determine the 
molecular mechanisms underlying ERRα antagonism, we probed the conformations of 
ERRα upon antagonist treatments. M13 phage display was used to screen for ERRα-
interacting peptides. We identified peptides that interact with ERRα in the activation 
function 2 (AF2) domain, some of which are able to distinguish the binding of different 
classes of ERRα antagonists. Cumulatively, these studies have explored the biological 
functions of ERRα and the molecular basis ERRα-mediated signaling pathways. 
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Chapter 1  Estrogen-related receptor  
1.1 Nuclear receptor superfamily 
Nuclear receptors comprise a superfamily of transcription factors that are 
responsible for a variety of physiological processes such as growth, development, 
homeostasis and reproductive function. The importance of nuclear receptors is 
underscored by their dysfunction in many diseases, including diabetes and various 
cancers. Out of the 49 human nuclear receptors identified, most members (except for the 
orphan nuclear receptors) can be regulated in terms of their transcriptional activities by 
small lipophilic molecules, such as steroid hormones, thyroid hormones, vitamin D, 
rexinoids, and fatty acids. Thus, these nuclear receptors serve as important regulators of 
gene transcription in response to extracellular signals.  
In the classic model of nuclear receptor action, the binding of ligands enables the 
receptors to undergo conformational changes that allow the receptors to form either 
homodimers or heterodimers. The dimeric receptor binds specific DNA response 
elements on target gene promoters and recruits cofactors. Different cofactors regulate 
diverse aspects of transcriptional initiation, from chromatin remodeling to recruitment 
of the basal transcription machinery. A key defining feature of this family, however, is 
that they do not possess DNA-binding activity and must be recruited by DNA-bound 
transcription factors. The recruitment of cofactors and the general transcription 
 2 
machinery results in increased transcription of target genes that mediate biological 
responses. 
While the first few nuclear receptors were identified by their ability to bind 
known ligands, more nuclear receptors were subsequently discovered based on 
sequence and structure similarities. However, not all of the newly discovered receptors 
have had their respective ligands identified. Nuclear receptors with no known ligands 
are considered orphan nuclear receptors until their endogenous ligands are identified. 
However, it is also possible that some orphan nuclear receptors may be constitutively 
active and thus do not require ligands. 
1.2 Nuclear receptor structure and function 
Despite the diverse functions of nuclear receptors, their structures are highly 
conserved. As shown in Figure 1.1, nuclear receptors consist of five or six functional 
domains. The DNA binding domain (DBD) and ligand/hormone binding domain (LBD), 
labeled as domains C and E respectively, are the most conserved motifs for almost all 
nuclear receptors.  
Region A/B located at the N-terminus of the nuclear receptor is the least 
evolutionarily conserved domain. In this domain, many nuclear receptors contain an 
activation function 1 region (AF-1), which acts in a ligand-independent manner.  
Region C, a highly conserved region that harbors the DNA-binding domain 
(DBD), is responsible for the recognition of hormone responsive elements on the 
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promoters of target genes. The DBDs of most NRs are well-characterized and the 
functional regions within DBDs have also been identified. The DBD of a NR binds to the 
major groves of the DNA helix through two zinc-finger motifs, which contains eight 
cysteines that interact with two zinc atoms (Glass 1994, Laudet 1997). As shown in 
Figure 1.2, in between the two zinc-finger motifs, the DBD domain also contains two 
other key regions, the Proximal-box (P-box) region and the Dimerization-box (D-Box) 
region. The P-Box determines the DNA binding specificity, while the D-Box is involved 
in nuclear receptor dimerization.  
Region D, a highly variable region between NRs, is less structured and can thus 
be considered as a flexible “hinge” between region C and region E. Region D has 
important roles in nuclear localization, heterodimerization and DNA binding.  
Region E, a strongly conserved domain consisting of 11-12 helices, is responsible 
for ligand binding and transactivation. Unlike AF-1, the AF-2 region in LBD recruits 
coactivators and transcriptional machinery in a ligand-dependent manner. Upon ligand 
binding, the LBD undergoes conformational changes that expose the hydrophobic AF-2 
pocket, which is the binding site for most of the coregulator proteins for transcriptional 
regulation. Usually, AF-2 pocket can interact with the LXXLL motif (where L is leucine 
and X any amino acid) of the coactivators. On many known coactivators, the Leucine 
residues form a hydrophobic surface on their α-helices, which can bind within the 
hydrophobic groove formed by helices three, four, five, and twelve of a nuclear receptor. 
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Without ligand binding, helix twelve is positioned away from the hydrophobic groove, 
thus the coactivator is unable to bind the receptor. Upon ligand binding, helix twelve 
changes its position, forming the completed hydrophobic groove for coactivator binding. 
Region F is only found in a few receptors and its function is largely unknown.
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Figure 1.1: Diagram of nuclear receptor structure and function. 
A. Schematic of domains A-F of nuclear receptors. The modular structure of NRs 
consists of seven (A-F) domains. The DNA-binding domain (DBD) in Region C and 
ligand-binding domain (LBD) in Region E are highly conserved. Region A/B contains the 
activation function 1 (AF-1), Region D has a flexible “hinge” between region C and 
region E, and Region F is of unknown function and is not well-conserved.  
B. The functional regions of the nuclear receptor DBD domain. Between the two 
zinc finger motifs for DNA binding, this domain contains a Proximal-box (P-box), which 
determines DNA sequence specificity, and a Dimerization-box (D-box), which forms 
part of the dimerization interface. 
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1.3 The orphan nuclear receptor subfamily of estrogen-related 
receptors (ERR) 
The estrogen-related receptors (ERR) are an orphan nuclear receptor subfamily 
consisting of three members: ERRα, ERRβ and ERRγ.  Compared with the restricted 
expression pattern of ERRβ, the subtypes of ERRα and ERRγ have wider distribution in 
both developing and adult tissues.  ERRα is expressed in almost all adult tissues, with 
higher expression levels in tissues with higher energy demands, such as the kidney, 
heart and brown adipocytes, suggesting its potential role in the regulation of energy 
balance (Sladek, Bader et al. 1997). Similar to the distribution pattern of ERRα, ERRγ is 
also widely expressed in adult tissues such as skeletal muscle, brain, kidney, and retina, 
with lower expression levels detected in adrenal, heart, pancreas, and thyroid tissues 
(Eudy, Yao et al. 1998, Chen, Zhang et al. 1999, Heard, Norby et al. 2000). The wide 
distribution pattern of the ERRs, especially ERRα and ERRγ, indicates that they are 
important for the development and maintenance of a variety of physiological processes. 
The estrogen receptor-related receptors were discovered using the DNA-binding 
domain of estrogen receptor alpha (ERα) as a probe to screen recombinant DNA 
libraries (Giguere, Yang et al. 1988).  Sequence comparisons show that ERRs and ERα 
share 66-70% sequence identity in the DBD and 34-37% in the LBD. Consistent with their 
high similarity in DBD sequences, ERRs and ERs also recognize similar DNA response 
elements containing the core motif 5’-AGGTCA-3’. While the classic Estrogen Response 
Element (ERE) is a palindromic sequence of 5’-AGGTCAnnnTGACCT-3’ with two core 
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motifs and three random nucleotides in between, the consensus Estrogen-related 
Receptor Response Element (ERRE) consists of an extended single motif: 5’-
TnAAGGTCA-3’. Both ERR and ER subfamilies can interact with the ERE and all 
members except ERβ can also recognize ERRE. Although ER and ERR can compete for 
the same DNA binding elements, ERα binds more efficiently to an ERE, while ERRs 
prefer an ERRE (Vanacker, Bonnelye et al. 1999).   
Unlike their high sequence similarity in DBD domain, ERRs and ERα exhibit 
more sequence divergence in the LBD.  Moreover, the ERRs were the first orphan 
nuclear receptors discovered and have not been shown to interact with any natural 
ligand, suggesting that these receptors may function without the need for ligands. 
Indeed, crystallographic studies of ERRα and ERRγ have revealed that the structure of 
the ERR LBD in the apo form is similar to those of agonist-bound NRs, suggesting that 
the LBD domain is already in a constitutively active conformation for coregulator 
binding (Greschik, Wurtz et al. 2002, Greschik, Flaig et al. 2004, Kallen, Schlaeppi et al. 
2004).  
1.4 Transcriptional regulation by ERRα 
Although ERRα has no natural ligand identified so far, it appears that ERRα 
utilizes a mechanism very similar to those previously described for other nuclear 
receptors to regulate gene transcription.  ERRα recognizes a specific ERR response 
element (ERRE) within target gene promoters and initiates the assembly of a large 
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complex of proteins, known as coregulatory proteins, which either positively or 
negatively regulate target gene transcription. Thus, these transcriptional coregulators are 
thought of as “protein ligands” of ERRα. It appears that ERRα activity can be regulated 
by alterations of the expression level and activity of its coregulators.  
The best-characterized coactivators for ERRα are members of the peroxisome 
proliferator-activated receptor-γ coactivator-1 (PGC-1) family of coregulators (Schreiber, 
Knutti et al. 2003). ERRα and its coactivator PGC-1 are known to regulate energy 
metabolism in tissues with high metabolic demands such as cardiac and skeletal 
muscles. Many of their target genes encode enzymes responsible for tricarboxylic acid 
(TCA) cycle, oxidative phosphorylation (OXPHOS) and lipid metabolism (Schreiber, 
Emter et al. 2004). Classical mapping studies, together with a recently completed ChIP-
chip analysis, have revealed that most of the metabolic gene targets of PGC-1/ERRα, 
such as rate-limiting enzymes in β-oxidation of fatty acids, the tricarboxylic acid (TCA) 
cycle and oxidative phosphorylation (OXPHOS), contain a canonical ERRE (Deblois, 
Hall et al. 2009). The requirement for this element has been established in a significant 
number of the direct targets of ERRα (Schreiber, Knutti et al. 2003, Huss, Torra et al. 
2004, Mootha, Handschin et al. 2004, Huss, Imahashi et al. 2007). 
In addition to the model of direct ERRE recognition stated above, ERRα may 
function together with other transcriptional factors and cofactors. Our laboratory has 
recently shown that ERRα can interact with β-catenin (β-cat) and enhance the 
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transcription of a reporter gene (TOP-flash) of β-cat (Dwyer, Joseph et al. 2010). It has 
been established in a definitive manner that β-cat interacts with members of the T-cell 
factor (TCF) family of factors, an interaction that is required for the activation of target 
gene transcription. We have also shown that endogenous β-cat and ERRα can physically 
interact when assayed by coimmunoprecipitation. The significance of this interaction 
was demonstrated by showing that both ERRα and β-cat were required for the positive 
regulation of a number of endogenously expressed genes that had previously been 
defined as β-cat target genes, some of which are important for cell migration. Thus, in 
the context of β-cat target gene transcription, it appears that ERRα fulfills the role of a 
transcriptional coactivator.  
Besides β-cat, ERRα has also been shown to physically interact with hypoxia-
inducible factor-1 (HIF-1) and stimulate its transcriptional activity (Ao, Wang et al. 
2008). HIF-1 is a transcription factor composed of two subunits: oxygen-regulated HIF-
1α and constitutively expressed HIF-1β.  Under hypoxic conditions, the HIF-1 dimer 
binds to specific hypoxia responsive elements (HREs) contained within the regulatory 
regions of hypoxia-induced genes (Wenger, Stiehl et al. 2005). The finding that ERRα can 
interact with HIF-1 suggests that ERRα may be recruited to the promoter of HIF-1 
regulated genes and serve as a transcriptional cofactor of HIF-1 in response to hypoxia. 
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1.5 Synthetic ERRα antagonists 
Although no endogenous ligands have been discovered for ERRs, several 
synthetic compounds have been shown to interact with ERRs. Some potent modulators 
of ERα have been shown to be relatively weak antagonists of ERRs. For example, 
diethylstilbestrol (DES), a potent synthetic estrogen that acts as an agonist on ER at nM 
concentrations, has been shown to act as an inverse agonist on ERRs at μM 
concentrations (Tremblay, Kunath et al. 2001). Similarly, 4-hydroxytamoxifen (4OH-
Tamoxifen), a synthetic selective estrogen receptor modulator (SERM), functions as an 
inverse agonist for ERRβ and ERRγ (Coward, Lee et al. 2001, Tremblay, Bergeron et al. 
2001).  
Progress has also been made in developing selective ERRα modulators, as shown 
in Fig 1.2. The first reported high throughput screening identified an ERRα-selective 
antagonist, XCT790 (Busch, Stevens et al. 2004), which inhibits ERRα transcriptional 
activity. This compound was used to define the specific role of ERRα in the regulation of 
metabolic signaling pathways (Mootha, Handschin et al. 2004, Willy, Murray et al. 2004). 
Mechanistically, XCT790 has been shown to cause ERRα degradation in vitro (Lanvin, 
Bianco et al. 2007). Compound A is a more recently discovered ERRα selective 
antagonist. Compound A is an effective inhibitor of ERRα activity when measured on 
endogenously expressed metabolic gene targets with minimal impact on ERRα stability. 
Thus, the activities of these two compounds on ERRα are not equivalent with respect to 
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gene transcription and receptor stability. They are reminiscent of the two classes of ERα 
antagonists, ICI182,780 (a selective estrogen receptor degrader, or SERD) and tamoxifen 
(a selective estrogen receptor modulator, or SERM), which have distinct biological 
activities. 
1.6 ERRα and breast cancer 
High ERRα level is associated with estrogen receptor (ER)-negative tumor status. 
ERRα is also correlated with the expression of ErbB2, an indicator of tumor 
aggressiveness (Ariazi, Clark et al. 2002). High expression and activity of ERRα has been 
shown to correlate with unfavorable clinical outcomes in breast cancer (Suzuki, Miki et 
al. 2004, Chang, Kazmin et al. 2011). These clinical outcomes are further supported by in 
vitro data where shRNA-mediated knock down of ERRα decreased tumor growth of 
MDA-MB-231 xenografts (Stein, Chang et al. 2008). Additionally, using synthetic ERRα 
antagonists, several groups have shown that inhibition of ERRα significantly reduces the 
growth of both ER-positive and ER-negative breast tumors (Bianco, Lanvin et al. 2009, 
Chisamore, Wilkinson et al. 2009). Although the precise function of ERRα remains 
unclear, these findings establish a causal role for ERRα in the pathogenesis of breast 
cancer. 
Different mechanisms have been proposed to describe how ERRα activity 
impacts tumor. PGC-1α/ERRα as metabolic regulators not only meet the high energy 
demand of rapidly growing tumors in vivo (Stein, Chang et al. 2008) but also cause 
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metabolic alterations that are associated with breast cancer brain metastasis (Chen, 
Hewel et al. 2007). Indeed, ERRα has been shown to be required for breast cancer cells to 
migrate in vitro (Stein, Chang et al. 2008).  
Besides the PGC-1α /ERRα signaling axes, ERRα has been found to collaborate 
with other transcription factors highlighting additional mechanisms by which ERRα can 
impact tumor growth and progression.  It has been shown that dedifferentiated 
epithelial tumor cells positioned at the invasion front exhibit a strong nuclear 
localization of β-cat, indicating that the nuclear function of β-cat may contribute to 
growth and metastasis of tumors (Hlubek, Brabletz et al. 2007).  Importantly, 
knockdown of ERRα and β-cat synergistically reduced the migration of breast cancer 
cells (Dwyer, Joseph et al. 2010). ERRα has also been reported to interact with HIF-1 and 
stimulate its transcriptional activity, suggesting that ERRα may be involved in initiating 
transcriptional responses that enable tumor cell adaptation to hypoxia, a response 
critical for tumor cell survival and growth (Harris 2002). Recently, VEGF, a well-known 
pro-angiogenesis factor in cancer, was identified as a target gene of ERRα, regulated 
either in a PGC-1α dependent (Arany, Foo et al. 2008, Stein, Gaillard et al. 2009, 
Klimcakova, Chenard et al. 2012) or a HIF-1 dependent manner (Ao, Wang et al. 2008). 
These studies suggest that ERRα may play a role in tumor angiogenesis through the 
transcriptional regulation of pro-angiogenic factors. Altogether, these data suggest that 
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ERRα is a key regulator of several important processes in breast cancer proliferation and 
progression. 
The limited treatment options for ER-negative and triple negative breast cancer 
necessitate the development of novel therapeutics for the treatment of this devastating 
disease. The association of ERRα with poor prognosis in breast cancer patients, 
combined with the demonstrated efficacy of ERRα inhibition in models of triple 
negative breast tumors, suggests that ERRα may be a novel target in the treatment of 
breast cancer.  The development of small molecule antagonists targeting this receptor 
and/or the signaling pathways associated with ERRα is impeded by the lack of 
understanding of the mechanism(s) by which ERRα activity impacts tumor biology and 
the structural basis of compounds that inhibit the activity of this receptor. Answers to 
these compelling questions will both inform and motivate future exploitation of ERRα as 
a therapeutic target within the settings of breast cancer. My thesis research focuses on 
three specific areas: (1) identification of ERRα target genes important for breast tumor 
pathogenesis, (2) characterization of the molecular basis of ERRα crosstalk with other 
transcriptional regulation pathways, and (3) characterization of the structural basis of 
ERRα antagonism, the completion of which we believe will aid the development of 
therapeutic strategies targeting ERRα. 
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 Figure 1.2: Structures of ERRα selective antagonists. 
Depiction of compounds with selective activity on ERRα.  A. A 
thiadiazolopyrimidinone derivative (XCT790) selectively inhibits ERRα activity and 
degrades the receptor. B. Compound A: N-[(2Z)-3-(4,5-dihydro-1,3-thiazol-2-yl)-1,3-
thiazolidin-2-yl idene]-5H dibenzo[a,-d][7]annulen-5-amine. 
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Chapter 2  ECM1, a novel target gene of ERRα 
Although the mechanism remains unclear, estrogen-related receptor alpha 
(ERRα) expression has been shown to correlate with unfavorable clinical outcomes and 
to play a causal role in the pathogenesis of breast cancer.  It was of particular 
significance, therefore, that we and others demonstrated that VEGF mRNA expression 
was positively regulated by ERRα, implicating angiogenesis as one mechanism by which 
this receptor impacts tumor biology.  Motivated by this observation we undertook a 
more extensive analysis of the target gene repertoire of ERR in breast cancer cells with 
the goal of identifying additional proteins that may be involved in breast tumor 
angiogenesis. The details of this study have been published previously (Stein, Chang et 
al. 2008). In brief, cells were infected with an adenovirus expressing PGC-1α, an obligate 
cofactor for ERR or with an adenovirus expressing a variant of PGC-1 that is unable 
to interact with the receptor.  This approach was used since no agonists of ERR have 
been identified thus far.  Bioinformatics analysis of the mRNA expression data 
confirmed that VEGF was upregulated upon ERR activation.  In addition, this analysis 
indicated that the expression of the mRNA encoding ECM1, a protein that has been 
shown to have angiogenic activities in other model systems, was upregulated under the 
same conditions.  Thus, analysis of the role of the ERR/ECM1 axis in validated models 
of breast cancer became the focus of our efforts in this area. The results of this analysis 
confirmed that ECM1 was a direct target of ERRα in cellular models of breast cancer.  
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Further, the angiogenic activity of ECM1 was confirmed in an in vitro tube formation 
assay.  Finally, we demonstrated for the first time that disruption of ECM1 expression 
dramatically reduced the growth of breast cancer xenografts.   
2.1 Introduction 
The estrogen-related receptor alpha (ERRα) is an orphan nuclear receptor (NR) 
that is widely expressed in all tissues of the body. High expression and activity of ERRα 
has been shown to correlate with unfavorable clinical outcomes in breast cancer (Suzuki, 
Miki et al. 2004, Chang, Kazmin et al. 2011). Importantly, shRNA-mediated knockdown 
of ERRα expression resulted in decreased growth of MDA-MB-231 breast cancer cells 
when propagated as xenografts (Stein, Chang et al. 2008).  Additionally, using synthetic 
ERRα antagonists, several groups have now shown that inhibition of ERRα significantly 
reduces the growth of both estrogen receptor (ER)-positive and ER-negative breast 
tumors (Bianco, Lanvin et al. 2009, Chisamore, Wilkinson et al. 2009). These findings 
establish a causal role for ERRα in the pathogenesis of breast cancer, although the 
precise mechanisms by which ERRα impacts tumor biology remain unclear.  
A natural ligand for ERR has not yet been identified, and it now appears likely 
that, unlike other members of the nuclear receptor superfamily, the activity of ERR is 
regulated by the expression level and/or activity of the PGC-1 (peroxisome proliferator-
activated receptor-γ coactivator-1) family of coactivators (Schreiber, Knutti et al. 2003). 
ERRα and its coactivator PGC-1 have been shown to regulate energy metabolism in 
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tissues with high metabolic demands such as cardiac and skeletal muscles. Many of their 
target genes encode enzymes responsible for the tricarboxylic acid (TCA) cycle, 
oxidative phosphorylation (OXPHOS) and lipid metabolism (Schreiber, Emter et al. 
2004).  Several non-exclusive hypotheses have been put forward to explain how ERRα 
impacts tumor biology. There is considerable data to suggest that the PGC-1α/ERRα 
complex helps in satisfying the high energy demand of rapidly growing tumors (Stein, 
Chang et al. 2008) and also facilitates the metabolic alterations that favor breast cancer 
brain metastasis (Chen, Hewel et al. 2007). There is also substantial data indicating that 
ERRα is also required for breast cancer cells to migrate in vitro (Stein, Chang et al. 2008).  
Taken together, these data suggest that ERRα is a key regulator of several important 
processes in breast cancer. The observation that VEGF, a well-known pro-angiogenic 
factor in cancer, can be regulated by ERRα and PGC-1α (Ao, Wang et al. 2008, Arany, 
Foo et al. 2008, Stein, Gaillard et al. 2009, Klimcakova, Chenard et al. 2012), suggests that 
PGC-1α/ERRα may play a role in tumor angiogenesis through the transcriptional 
regulation of pro-angiogenic factors. Interestingly, in our microarray analysis of PGC-
1α/ERRα-induced gene transcription (Stein, Chang et al. 2008, Chang, Kazmin et al. 
2011)  we noticed a dramatic induction of the mRNA encoding ECM, a protein which 
has previously been shown to be overexpressed in human breast tumors and for which 
an angiogenic role has been demonstrated.  
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Extracellular matrix protein 1 (ECM1) is a secreted glycoprotein. A loss-of-
function mutation in ECM1 has been shown to cause genodermatosis lipoid proteinosis 
(Hamada, McLean et al. 2002), suggesting that ECM1 plays an important role in 
maintaining the structural and functional integrity of the skin. In this regard, it has been 
shown that ECM1 can interact with various extracellular matrix proteins in skin, such as 
perlecan, fibulin-1C/D, MMP-9, collagen type IV and laminin 332 (Mongiat, Fu et al. 
2003, Fujimoto, Terlizzi et al. 2005, Fujimoto, Terlizzi et al. 2006, Sercu, Zhang et al. 2008, 
Sercu, Lambeir et al. 2009). Interestingly, ECM1 is overexpressed in a significant number 
of primary and/or metastatic tumors: invasive breast ductal carcinoma (83%), 
esophageal squamous carcinoma (73%), gastric cancer (88%) and colorectal cancer (78%) 
(Wang, Yu et al. 2003). Furthermore, ECM1 expression has been identified as a novel 
prognostic marker for poor long-term survival in breast carcinoma (Lal, Hashimi et al. 
2009) and a predictor of the chemo-resistance in ovarian cancer patients (Pan, Cheng et 
al. 2009). ECM1 expression also correlates with the metastatic properties of epithelial-
derived tumors and has been established as a novel prognostic factor for the metastatic 
potential of hepatocellular carcinoma (Chen, Jia et al. 2011). The highest expression of 
ECM1 in tumors is found around blood vessels, and a potential role for ECM1 in 
angiogenesis has been proposed due to its ability to stimulate endothelial cell growth in 
vitro and blood vessel formation in chicken embryos in vivo (Han, Ni et al. 2001). 
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Together, these data highlight the potential importance of our observation that ECM1 is 
a mediator of the pathogenic activities of ERR in breast tumors. 
In the present study, we undertook studies to (1) define the molecular 
mechanism(s) by which PGC-1α/ERRα impact ECM1 expression (2) establish the 
importance of ECM1 in angiogenesis and (3)  evaluate the impact of ECM1 knockdown 
on the growth of breast tumor xenografts in vivo.  The results of these studies 
demonstrate a significant role for ECM1 in the establishment of the tumor environment 
and provide a mechanism to explain the negative impact of ERR expression on breast 
tumor pathology.  
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2.2 Materials and Methods 
2.2.1 Cell culture. 
All cell lines, unless otherwise noted, were obtained from ATCC (Manassas, VA), 
expanded for two passages, and cryopreserved. All experiments were performed with 
cells of passage less than 25. MDA-MB-231 cells and the 4175 metastatic subline of this 
cell line (Minn, Gupta et al. 2005) (gift from Joan Massague, Memorial Sloan-Kettering 
Cancer Center, New York, NY, USA) were cultured in DMEM. MDA-MB-436, SKBR3 
and HCT-116 cells were cultured in RPMI. MCF-7 cells were cultured in DMEM/F12. 
The stable MDA-MB-231-4175-derived cells were grown in DMEM supplemented with 
puromycin. All media above were purchased from Invitrogen and supplemented with 
8% fetal bovine serum, 0.1 mM non-essential amino acids and 1 mM sodium pyruvate. 
HMEC-1 (gift from Gerard Blobe, Duke University, Durham, NC, USA) were cultured 
on 0.02% gelatin-coated plate in MCDB-131 (Invitrogen) supplemented with 10% FBS, 1 
ug/ml hydrocortisone, 10 ng/ml EGF and 2 mM L-glutamine (Tian, Mythreye et al. 2012). 
IHMVEC cells (gift from Xiaofan Wang, Duke University, Durham, NC, USA) were 
cultured in EGM-2MV (Lonza) (Curtis, Wang et al. 2013). All cell lines were grown at 
37°C in a humidified 5% CO2 atmosphere.  
2.2.2 Transduction of adenoviruses. 
The generation of adenoviruses has been previously described (Gaillard, Dwyer 
et al. 2007). Cells were infected with adenoviruses expressing β-galactosidase (Bgal) or 
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PGC-1α (WT, 2X9, and L2L3M) at MOI of 100 and harvested after 48 hours. For siRNA 
experiments, cells were pre-transfected with indicated siRNA 48 hours prior to 
adenovirus infection, and harvested 24 hours after adenovirus infection. 
2.2.3 RNA preparation and analysis. 
Total RNA was extracted from cultured cells using the Bio-Rad Aurum RNA 
purification kit. Total RNA was extracted from tumor samples using a modified TRIzol 
(Invitrogen) RNA Purification protocol. 0.5 μg of isolated total RNA was used to 
synthesize cDNA using the iScript cDNA synthesis kit (BioRad). Real-time PCR was 
performed using the CFX384 Real-Time System (BioRad) with 0.06 μl cDNA, 0.3 μM 
primers and iQ SYBRGreen supermix (BioRad). cDNA was quantified using the 2-ΔΔCt 
method (Livak and Schmittgen 2001). Data were normalized to the expression of either 
36B4 or RSP18. Cell culture data is representative of three independent experiments, 
while tumor data is the mean ± SEM. 
2.2.4 Immunoblotting. 
Whole-cell extracts were obtained by lysing cells in RIPA buffer (50 mM Tris-HCl 
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% Na-deoxycholate, 0.1% SDS 
and protease inhibitors (5 µg/ml aprotinin, 5 µg/ml leupeptin,1 mM PMSF)). Secreted 
proteins were collected for analysis following the culture of cells in serum-free media for 
24 hours. StrataClean Resins (Agilent Technologies, 400714-61) were used to precipitate 
proteins in the media. Proteins were separated by 8% SDS-PAGE and transferred onto 
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Hybond-C Extra nitrocellulose membrane (Amersham Biosciences) or Odyssey 
nitrocellulose membrane (LI-COR). Rabbit anti-PGC-1α antibody (Santa Cruz sc-13067, 
1:1000 dilution), rabbit anti-ERRα antibody (Epitomics 2131-1, 1:1000 dilution), rabbit 
anti-ECM1 antibody (Epitomics 5447-1, 1:1000 dilution) and goat anti-GAPDH (V-18) 
antibody (Santa Cruz sc-20357, 1:1000 dilution) were used for protein detection. 
Secondary antibodies: Goat Anti-Rabbit IgG (H+L)-HRP (BIO-RAD 170-6515) and 
Donkey anti-Goat IgG-HRP (Santa Cruz SC-2033) were used for signal detection using 
autoradiography; CF770 Goat Anti-Mouse IgG (H+L) (Biotium 20077), CF770 Goat Anti-
Rabbit IgG (H+L) (Biotium 20078) and CF770 Donkey Anti-Goat IgG (H+L) (Biotium 
20277) were used for signal detection by Odyssey Infrared Imager (LI-COR). 
2.2.5 Generation of inducible ECM1 knock-down stable cells. 
ECM1 siRNA and control siRNA oligonucleotides were ligated into Tet-pLKO-
puro vector (Addgene plasmid 21915). 7.5 μg of these constructs were mixed with 3.75 
μg pVSVG and 3.75 μg pCMVdR8.2.dvpr and cotransfected (FuGene 6, Roche Applied 
Science) into the HEK293FT packaging cell line. Viral supernatant was filtered and 
supplemented with 8μg/ml polybrene. MDA-MB-231-4175 cells were infected by viral 
supernatants, and the derivative stable cells were selected under 1 μg/ml puromycin. 
The knock-down of ECM1 expression was induced by 200 ng/ml doxycycline and 
verified by RT-qPCR and Western blot analysis. 
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2.2.6 Endothelial tube formation assay. 
HMEC-1 cells were plated at a density of 60,000 cells per well in 24-well plates 
coated with Growth Factor Reduced Basement Membrane Matrix (BD Matrigel 356231, 
BD Biosciences). Endothelial cells were cultured for 24 hours in serum-free basal media 
supplemented with 100-200ng/ml recombinant human ECM1 (R&D systems 3937-EC-
050) to stimulate tube formation. 20-50ng/ml recombinant VEGF (Pepro Tech 100-20) 
was used as positive controls for tube formation. Each test concentration was assayed in 
duplicate wells and two independent biological replicates of each assay were performed. 
Representative field images were collected by an AMG EVOS XL microscope and tube 
formation was quantified using Angiogenesis Analyzer for ImageJ (Carpentier 2012). 
2.2.7 Tumor xenograft study. 
Animal handling and procedures were approved by the Duke University 
Medical Center Institutional Animal Care and Use Committee. For these studies 1x106 
MDA-MB-231-4175 shCON, shECM1(a) or shECM1(b) cells were suspended with 50% 
Basement Membrane Matrix (BD Matrigel 354234, BD Biosciences) in DMEM and were 
orthotopically grafted into the inguinal mammary fat pad of 8 week-old female NSG 
(NOD Scid Gamma) mice (10 mice per group). Water, provided ad libitum, was 
supplemented with 2mg/ml doxycycline starting three days prior to the cell graft and 
maintained throughout the experiment. To control for the potential off-target effects of 
doxycycline, one extra group of mice (n=8) were injected with shControl cells and 
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provided with normal water (no doxycycline).  23 days after cell graftment, half of the 
mice in each of the groups that were on doxycycline were switched to normal water. 
Tumor measurements were taken every 2 days. The volume of the primary tumors was 
quantified by direct caliper measurements (volume = width2 x length/2). Tumors were 
removed when they reached a maximum of 2000 mm3 and frozen in liquid nitrogen. 
Statistical analyses. Tumor growth was analyzed by two-way ANOVA followed 
by Bonferroni posttests, where significance was set at P<0.05.Tumor mRNA was 
analyzed by students T test comparing each shECM1 to shControl. 
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2.3 Results 
2.3.1 ECM1 is a target gene of the PGC-1α/ERRα signaling axis. 
There is abundant evidence implicating ERRα in the pathogenesis of breast 
cancer, although the mechanism(s) by which the receptor impacts processes of 
pathological importance remains unclear.  As a first step in defining the targets of ERR 
action in breast cancer, we performed a bioinformatics analysis of the mRNA expression 
data that were collected following the activation of ERR by expressing its cofactor 
PGC-1 In this manner, it was determined that the mRNA encoding ECM1 was one of 
the most strongly upregulated genes in breast cancer cells (Stein, Chang et al. 2008).  In 
addition to ERR, PGC-1α can transcriptionally activate several other nuclear receptors.  
To specifically implicate ERR in the induction of ECM1 expression, we confirmed that 
the induction was maintained when a specificity mutant of PGC-1, PGC-1α 2x9, 
developed previously by our laboratory to selectively activate ERR, was introduced 
into cells (Gaillard, Grasfeder et al. 2006, Gaillard, Dwyer et al. 2007).  Further, as a 
negative control, we used a PGC-1variant, PGC-1α L2L3M, in which the nuclear 
receptor interacting domain in this coregulator was mutated.  A β-galactosidase (βgal) 
expressing adenovirus also served as a negative control for these studies. Using these 
tools, we confirmed in four different breast cancer cell lines that ERRα activation by 
PGC-1α wild type or the ERRα-specific PGC-1α 2x9 mutant resulted in an upregulation 
ECM1 mRNA. We confirmed in MCF-7 cells that ECM1 protein was likewise induced 
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(Figure 2.1).  To verify that the induction of ECM1 by PGC-1α was mediated by ERRα, 
we evaluated its expression in cells with siRNA-mediated knockdown of ERRα 
expression.  As expected, in the absence of ERRα, neither PGC-1α nor PGC-1-2X9 was 
able to induce the expression of either ECM1 mRNA or protein (Figure 2.2). It was 
concluded, therefore, that ECM1 is a bona fide target of the PGC-1α/ERRα complex. This 
finding, coupled with the fact that ECM1 overexpression had been found to be 
associated with invasive breast carcinoma, motivated our continued investigation into 
the biological implications of ECM1 upregulation in breast cancer. 
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Figure 2.1 Upregulation of ECM1 by ERRα/PGC-1α in breast cancer cells. 
A, PGC-1α induces ECM1 mRNA expression. Cells were infected with 
adenoviruses β-galactosidase (Bgal), wild-type PGC-1α (WT), PGC-1α 2X9 mutant (2X9) 
or PGC-1α L2L3M mutant (L2L3M) as indicated, followed by qPCR analysis of ECM1 
mRNA levels normalized to 36B4 and relative to Bgal, and represented as mean ± SEM 
of triplicate wells in a representative assay.  
B, Western blot analysis of secreted ECM1. Cells were changed to serum-free 
media 24 hours before media collection and proteins precipitated from culture media 
were analyzed by western blot. 
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Figure 2.2 The upregulation of ECM1 by PGC -1α is ERRα-dependent. 
A, PGC-1α mediated induction of ECM1 mRNA expression is dependent on 
ERRα expression. Cells were subjected to mock transfection or transfected with control 
siRNAs (luc, med), or siRNAs directed against ERRα (siERRαA, siERRαB) or ECM1 
(siECM1) for 48 hours and subsequently infected with adenoviruses as indicated. ECM1 
mRNA levels were assessed by RT-qPCR, normalized to 36B4 and relative to mock-Bgal, 
and represented as mean ± SEM of triplicate wells in representative assay.  
B, PGC-1α mediated-induction of ECM1 protein expression is dependent on 
ERRα expression. siRNA transfection and adenovirus infection were as described in (A). 
Cells were changed to serum-free media 24 hours before media collection. Whole-cell 
extracts and proteins precipitated from culture media were analyzed by western 
immunoblot. 
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2.3.2 The role of ECM1 on breast cancer proliferation in vitro. 
As a first step in defining the functional role of ECM1 and how this may relate to 
breast cancer pathogenesis, we generated a series of derivatives of the MDA-MB-231-
4175 cell line, a well-validated model of breast cancer that can be propagated as a 
xenograft in immunocompromised mice (Minn, Gupta et al. 2005). For these studies, 
several derivatives of this cell line were constructed by lentiviral transduction and 
puromycin selection to obtain inducible expression of shRNA directed against ECM1 or 
a scrambled control shRNA. Two independent shRNAs directed against different 
regions in the ECM1 transcript, shECM1(a) and shECM1(b), were included to control for 
potential off-target effects. Characterization of the stable inducible shRNA lines (MDA-
MB-231-4175 shECM1(a), shECM1(b) and shControl) demonstrated a quantitative 
inhibition of ECM1 expression in both shECM1 cell lines upon doxycycline induction as 
compared to what was observed in the control cell line (Figure 2.3).  
We next evaluated the effect of ECM1 knockdown on the proliferation of the 
stable cell line derivatives in vitro. Somewhat surprisingly, we determined that altering 
ECM1 expression level had no effect on the cell growth rate under the conditions 
studied (Figure 2.4).  Similarly, siRNA-mediated ECM1 knockdown was also without 
effect on MDA-MB-231 and MDA-MB-436 breast cancer cell lines.   
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A                                                   B  
 
C 
 
Figure 2.3 Characterization of inducible stable cells expressing ECM1 shRNA 
A, Real Time PCR of ECM1 expression in MDA-MB-231-4175 shCON, shECM1-a 
and shECM1-b cells with or without 200ng/ml doxycycline treatment. Data are 
normalized to 36B4 and shown as a fraction of shControl mRNA ± SEM of triplicate 
wells of a representative assay.  
B, Western immunoblot analysis of ECM1 protein secreted from MDA-MB-231-
4175 shControl, shECM1-a or shECM1-b cells with or without 200ng/ml doxycycline 
treatment. GAPDH serves as the loading control.  
C, Quantification of western immunoblot in B was performed using LiCor 
densitometry software. 
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Figure 2.4 ECM1 Silencing does not affect breast cancer cell proliferation in 
vitro. 
MDA-MB-231-4175 shControl, shECM1-a and shECM1-b cells were seeded in 96-
well plates at a density of 3,000 cells/well with or without 200ng/ml doxycycline. Plates 
were harvested on the indicated days after seeding. Cell numbers were determined by 
Fluoreporter assay for DNA content using Hoechst 33258 (Sigma). The fluorescence was 
read at excitation 346nm and emission 460nm using a Fusion microplate reader 
(PerkinElmer, Waltham, MA). Data was plotted as cell number ± SEM of triplicate wells 
in representative assay.  
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2.3.3 Decreased ECM1 expression impedes breast tumor growth in 
mice. 
We were surprised, given the significant correlation between ECM1 expression 
and breast tumor aggressiveness, that ECM1 knockdown was without effect on breast 
cancer cell proliferation in vitro. Thus, we next proceeded to evaluate the impact of 
ECM1 knockdown on the growth of the same cell lines when propagated as xenografts 
in immunocompromised mice. Specifically, MDA-MB-231-4175 shECM1 (a), shECM1 (b) 
or shControl cells were orthotopically grafted into the mammary fat pads of female NSG 
(NOD Scid Gamma) mice. Both real time PCR and immunoblot analyses (Figure 2.5) of 
the resulting primary tumors revealed that ECM1 levels were decreased in the shECM1 
xenografts. Importantly, and in contrast to our findings in vitro, shRNA-mediated 
knockdown of ECM1 significantly impeded the growth of tumors when compared to a 
control shRNA (Figure 2.6). This important finding suggests that ECM1 is important for 
tumor growth in vivo and that this effect is manifest in the complex tumor 
microenvironment.    
To test whether ECM1 affected tumor angiogenesis, we examined CD31 
expression in the xenograft tumors. We found CD31 mRNA was decreased in the MDA-
MB-231-4175 shECM1-derived tumors (Figure 2.7A). Furthermore, when the data from 
all treatment groups were combined, a significant correlation between ECM1 and CD31 
expression was observed (slope = 0.1558, R2 =, P<0.0001) (Figure 2.7B).  Thus, the effects 
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of ECM1 on tumor growth are likely to be mediated, at least in part, by its ability to 
promote angiogenesis. 
2.3.4 ECM1 protein stimulates angiogenesis of endothelial cells in 
vitro. 
Given the dramatic effect of ECM1 knockdown on xenograft growth and the 
correlation of this activity to decreased CD31 expression, we next evaluated the potential 
angiogenic activity of purified ECM1 protein when assayed in vitro. To this end, we 
performed an in vitro endothelial cell tube formation assay. Specifically, Human 
Microvascular Endothelial Cells (HMEC-1) were cultured on a reduced growth factor 
containing basement membrane matrix (Matrigel). Cells initially attached to the matrix, 
then elongated and migrated toward each other to form capillary-like tubes. As shown 
in Figure 4.8 A, although elongated processes appeared in the control cells cultured in 
basal media for 24 hours, only a few short, thin tubes were formed and appeared as 
disconnected networks. In contrast, in the presence of ECM1 (100-200ng/ml) or VEGF 
(20-50ng/ml), endothelial cells formed longer, thicker tubes, and the branches were 
strongly connected as networks. Quantification of the tube formation images shows that 
ECM1 stimulates the formation of nodes, joints, segments and branches (Figure 2.8 B). 
Importantly, a similar effect of recombinant ECM1 was observed in the tube formation 
assay where the transformed IHMVEC endothelial cell line was used (Figure 2.8 C). 
The membrane receptor or binding proteins that interact with ECM1 and the 
signaling events downstream of these activities are not known.  As a first step in 
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defining the ECM1 signaling pathway, we asked whether it acts on endothelial cells in a 
manner that is similar to VEGF. Notably, VEGF has been shown to stimulate 
phosphorylation of VEGFR, an activity that initiates a signaling cascade that results in 
activating phosphorylation of Erk, Akt and p38. However, treatment of (HMEC-1 cells) 
with ECM1 did not result in the phosphorylation of any of these targets. Surprisingly, 
we did not observe any synergism between ECM1 and VEGF when added to cells in 
different ratios.  Thus, the mechanism by which ECM1 manifests its angiogenic activity 
remains elusive and will require further investigation to be elucidated.  
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Figure 2.5 Confirmation of conditional knockdown of ECM1 expression in 
MDA-MB-231-4175 cell - derived xenografts 
A, Expression of human ECM1 mRNA was measured by Real-time PCR and 
normalized to human RSP18 mRNA expression. Three groups of mice were used for 
data analysis. Group I,II and III: mice injected with shControl cells, shECM1-A cells or 
shECM1-B cells and treated with doxycycline water (n=5).  Differential expression of 
ECM1 was observed between the shControl and shECM1 groups (P<0.05).  
B, The impact of ECM1 mRNA knockdown on ECM1 protein expression in 
tumor xenografts was confirmed by Western immunoblot analysis. GAPDH serves as 
the loading control. 
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Figure 2.6 Silencing of ECM1 decreases the growth of MDA-MB-231-4175 cell-
derived xenografts 
Tumor growth rate of the stable cell lines after orthotopic injection. MDA-MB-
231-4175 shCON, shECM1(a) and shECM1(b) cells were injected into the mammary fat 
pad of NSG (NOD Scid Gamma) mice fed with 2mg/ml doxycycline containing water 
starting three days prior to the cell injection. Tumor measurements were taken every 2 
days, while the volume of the primary tumors was quantified by direct caliper 
measurements (volume = width2 x length/2). Tumor growth was analyzed by two-way 
ANOVA followed by Bonferroni posttests. Points: mean volume for 10 mice per cell line. 
Bars: SEM. Stars: P < 0.05. 
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Figure 2.7 The expression of CD31 associates with ECM1 level in tumors 
A, Expression of mouse CD31 in vivo. CD31 mRNA expression was measured by 
Real-time PCR and normalized to human RSP18 expression (n=5).  
B, Correlation between mouse CD31 and human ECM1 expression in tumor 
xenografts.  For this study, the expression of CD31 and ECM1 was evaluated in all mice 
(n=38) from all treatment groups and the data were plotted together to show the 
relationship between ECM1 and CD31 expression in tumors (P<0.0001). 
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Figure 2.8 ECM1 stimulates tube formation of endothelial cells in vitro 
A, ECM1 (200ng/ml) stimulates HMEC-1 tube formation. In this study, VEGF 
(50ng/ml) treatment served as a positive control. Images are representative of duplicate 
wells and two independent biological replicates. HMEC-1 cells were plated in 24-well 
plates coated with growth factor reduced Basement Membrane Matrix and cultured in 
serum-free basal media for between 6-24 hours as indicated. 
B, Quantification of HMEC-1 tube formation shows the angiogenic effect of 
ECM1. Images were processed using “Angiogenesis Analyzer for ImageJ” and data from 
each treatment were plotted as mean ± SEM of 6-8 pictures from two independent wells.  
C. Immortalized Human Microvascular Endothelial cells (IHMVEC) were 
cultured on Matrigel containing regular basement membrane matrix. IHMVEC cells 
were plated at a low density of 2,000 cells per well in 96-well plates. Cells were cultured 
in serum-free basal media for between 6 to 24 hours as indicated. Most of the control 
cells cultured in basal media were rounded and grew as solitary cells. Only a few tubes 
were observed arranged as disconnected networks in this control condition. In contrast, 
in the presence of ECM1 (100-200ng/ml) or VEGF (100ng/ml), a substantial number of 
endothelial cells formed tubes were organized as connected networks. Tube numbers 
were manually counted using imageJ software and represented as mean ± SEM of 
triplicate wells. 
  
 41 
2.4 Discussion 
Previous studies have demonstrated a relationship between ECM1 expression 
and poor prognosis in both breast and liver cancers (Lal, Hashimi et al. 2009, Chen, Jia et 
al. 2011). Nevertheless, a causal relationship between ECM1 and cancer has not been 
established. It is significant, therefore, that we were able to demonstrate that ECM1 
knockdown has a dramatic inhibitory effect on breast tumor growth in mice and that 
this is likely related to decreased angiogenesis. Additionally, these studies further 
validate the utility of targeting ERR and ECM1 expression in breast cancer.  
Although ECM1 is overexpressed in breast, esophageal, gastric and colorectal 
cancers, the mechanisms by which its expression are regulated have not been elucidated. 
In this study, we demonstrate that ECM1 is a downstream target of the PGC-1α/ERRα 
signaling complex, and as such, may be a key mediator of the pathogenic activities of 
ERR noted in various cancers. 
Currently, the role of PGC-1α in cancer remains controversial, and it appears its 
actions may be highly context- dependent. For example, PGC-1α overexpression has 
been observed in endometrial cancer (Cormio, Guerra et al. 2009) while several other 
studies have reported reduced PGC-1α expression in cancers of the breast (Watkins, 
Douglas-Jones et al. 2003, Watkins, Douglas-Jones et al. 2004) and colon (Feilchenfeldt, 
Brundler et al. 2004) as well as the surface epithelium of malignant ovarian tumors 
(Zhang, Ba et al. 2007). Additionally, overexpression of PGC-1α was shown to stimulate 
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ovarian cancer cell apoptosis though a PPAR gamma-dependent pathway, (Zhang, Gao 
et al. 2007) and PGC-1α promotes prostate cancer cell growth by activating the androgen 
receptor (Shiota, Yokomizo et al. 2010). ErbB2/Neu-induced mammary tumors with 
ectopic PGC-1α overexpression exhibited an increased glucose supply and increased 
tumor growth (Klimcakova, Chenard et al. 2012). PGC-1α was also shown to 
coordinately regulate mitochondrial and fatty acid metabolism, and, thus, promote 
colon tumor growth (Bhalla, Hwang et al. 2011). From these studies, it seems likely that 
PGC-1α may have multiple roles depending on different biological contexts, potentially 
due to its interaction with different nuclear receptors. Our study identified ECM1, a 
novel pro-angiogenic factor, to be a target gene of the PGC-1α/ERRα axis, which 
suggests that PGC-1α/ERRα may function through the promotion of tumor angiogenesis 
to adapt to the lack of nutrient sources in rapidly growing tumors 
Previously, ECM1 was reported to contribute to the invasion and migration of 
cholangiocarcinoma cells (CCA) (Xiong, Zhang et al. 2012).  However, under the 
conditions of our assays ECM1 knockdown had no effect on the proliferation or the 
migratory/invasive properties of several breast cancer cell lines (MDA-MB-231 and 
MDA-MB-436). Thus, it is tempting to speculate that although breast cancer cells can 
secrete ECM1, they may not be the primary effector of ECM1. Instead, secreted ECM1 
may exert its actions on endothelial cells within the tumor microenvironment and 
stimulate blood vessel formation.  In support of this hypothesis we found that 
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expression of ECM1 correlates with CD31 in tumors and that recombinant ECM1 can 
induce endothelial cell tube formation in vitro. Identification of the ECM1 
receptor/binding protein (if such a protein exists) and subsequent evaluation of its 
expression will provide clarity as to the validity of this model.  However, it has been 
reported that ECM1 can interact with many extracellular matrix proteins (such as MMP-
9) in cultured skin cells. Thus it is possible that ECM1 may have a direct effect on the 
remodeling of the extracellular matrix, an activity that would not require the 
involvement of a specific receptor.  
In addition to the local effects of ECM1 on tumor vasculature highlighted by our 
studies, there is considerable data to suggest that it may also have systemic effects.   
Notably, clinical studies indicate that high ECM1 levels could be detected in serum 
samples from patients with ovarian carcinoma (Boylan, Andersen et al. 2010).  It has 
been reported that ECM1 can bind to the IL-2 receptor on the surface of Th2 cells to 
block IL-2 signaling and promote Th2 cell egress from lymph nodes  (Sahin, Colla et al. 
2011). It is also known that Th2 cells can infiltrate breast cancer tumors and promote 
tumor growth (Pedroza-Gonzalez, Xu et al. 2011). Thus, it is possible that ECM1 may 
promote breast tumor development through recruitment of Th2 cells. However, we 
observed a dramatic effect of ECM1 knockdown on tumor growth in T-cell deficient 
mice.  Thus, any effects of ECM1 on T-cells, and subsequently on tumor biology, are 
beyond the effects we have noted on angiogenesis.  
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Although the molecular mechanisms underlying the angiogenic actions of ECM1 
remain to be determined, our preliminary study suggests that ECM1 functions in a 
manner that is distinct from VEGF. We show that unlike VEGF, ECM1 does not trigger 
phosphorylation of VEGFR, Erk, Akt or p38. Recently, a predicted structural model for 
ECM1 using the third human serum albumin as template divided ECM1 into four 
domains: an N-terminal domain of α-helices, followed by three Serum Albumin 
Subdomain-Like domains (SASDL 2-4). It is proposed that the SASDL domains of ECM1 
could form a “finger-like” structure for ECM1 to serve as a scaffolding protein 
interacting with a variety of extracellular proteins (Sercu, Lambeir et al. 2009). Our in 
vivo study shows that alteration of ECM1 can affect the CD31 levels in tumors without 
changing VEGF levels. A number of drugs that target VEGF-A or its receptor have been 
developed to successfully halt tumor angiogenesis and impede tumor growth in animal 
studies. However, the clinical results in cancer patients have been less impressive. The 
discovery that ECM1 is a pro-angiogenic factor in tumors may provide an alternative 
strategy to target tumor angiogenesis. 
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Chapter 3  Crosstalk of ERRα with other signaling 
pathways 
3.1 Introduction 
3.1.1 Canonical pathway of ERRα 
ERRα has no known natural ligand identified so far. However, the apo ERRα 
protein appears to be in the “active” conformation similar to the structures of other 
agonist-activated nuclear receptors (Greschik, Wurtz et al. 2002, Kallen, Schlaeppi et al. 
2004). This finding raises the question as to how the transcriptional activity of ERRα is 
regulated. 
Cofactor availability and activity are likely to be the main mechanism by which 
ERRα activity is regulated. Indeed, it has been shown that ERRα activity can be 
dramatically upregulated by increasing the expression of its coactivators PGC-1α and 
PGC-1β, which in turns is regulated by metabolic stresses, such as fasting, exercise and 
cold (Kamei, Ohizumi et al. 2003, Schreiber, Knutti et al. 2003, Huss, Torra et al. 2004). 
Together, this cofactor/receptor pair regulates the transcription of a large number of 
genes involved in energy metabolism. Chromatin immunoprecipitation (ChIP) analyses 
have revealed that most of the metabolic gene targets of PGC-1/ERRα contain a 
canonical ERR response element (ERRE) (Deblois, Hall et al. 2009). The mechanism by 
which ERRα regulates the transcription of these genes is very similar to that previously 
described for other nuclear receptors. ERRα recognizes ERRE within target gene 
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promoters and initiates the assembly of a large complex of cofactors and general 
transcription machinery that together enable the regulation of target gene transcription. 
3.1.2 Non-canonical gene regulation by ERRα 
Besides this classical model of direct ERRE binding, emerging evidences also 
suggest the existence of alternative pathways by which ERRα regulates target gene 
transcription. Specifically, ERRα can interact or cooperate with other transcriptional 
factors or cofactors besides PGC-1 to effect target gene transcription.  β-catenin (β-cat) 
and hypoxia-inducible factor-1 (HIF-1) are two of such factors we are particular 
interested in because of their relevance to cancer. 
ERRα/β-cat pathway 
Previously, our lab used a chemical biology approach to explore the pathways in 
which ERRα is engaged (Dwyer, Joseph et al. 2010). Among the compounds identified to 
modulate the transcriptional activity of ERRα were carbolines, which were known to 
inhibit the canonical Wnt signaling pathway. In the canonical Wnt pathway, Wnt 
activation causes GSK-3β inhibition, which leads to an increase in β-cat stability. The 
stabilized β-cat can translocate to the nucleus, where it regulates target gene expression 
through its interaction with the T-cell factor (TCF)/ lymphoid enhancer-binding factor 
(LEF) family of transcription factors. TOPFlash is a TCF-LEF luc-reporter, the activity of 
which is driven by TCF/LEF and enhanced by the binding of cofactor β-cat. While ERRα 
expression alone has a minimal effect on TOP-flash, it strongly enhanced the 
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transcription of this reporter gene in the presence of a constitutively active β-cat mutant. 
Similarly, expression of β-cat significantly enhanced the activity of ERRα on 3xERE_luc 
reporter. The crosstalk between ERRα and β-cat was further demonstrated by 
coimmunoprecipitation studies, which showed that endogenous ERRα physically 
interacts with β-cat and TCF. That being said, however, it does not rule out the 
possibility that ERRα and β-cat/TCF complexes bind independently on target genes and 
cooperate to regulate target gene transcription. One example of this is Wnt 11, a gene 
involved in cell migration, which was identified to be under the control of this ERRα/ β-
cat crosstalk (Dwyer, Joseph et al. 2010). Interestingly, ChIP analysis indicated that both 
ERRα and β-cat were recruited to the same promoter region of Wnt-11, where several 
putative ERREs and TCF binding sites were found to be adjacently located.  What 
remains unclear is the mechanism of this crosstalk, as whether ERRα and β-cat bind to 
adjacent sites or if a tethering mechanism is involved.  
ERRα / HIF-1 pathway 
The transcription factors hypoxia inducible factor 1 alpha (HIF-1α) and beta 
(HIF-1β) form a heterodimer to regulate the physiological adaptation to hypoxia. While 
the protein level of the β-subunit is relatively constant, the α-subunit is highly oxygen 
sensitive (Wenger, Stiehl et al. 2005). Under normoxia conditions, HIF-1α is 
hydroxylated on proline 402 and proline 564, which is necessary for binding to von 
Hippel-Lindau (VHL), a component of an E3 ubiquitin ligase complex, and triggers 
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ubiquitin-mediated HIF-1α degradation by the proteasome. Prolyl hydroxylases need 
O2, ferrous iron and 2-oxoglutarate for their activity. However, under hypoxia 
conditions, the absence of O2 inactivates prolyl hydroxylase activity, thus stabilizing the 
HIF-1α protein. Under normoxic conditions, prolyl hydroxylase inhibitors such as cobalt 
chloride (CoCl2), desferrioxamine (DFO) and dimethyloxaloylglycine (DMOG) can block 
HIF-1α degradation. While CoCl2  and DFO are iron chelators, DMOG is a 2-
oxoglutarate analogue . Stabilized HIF-1α dimerizes with HIF-1β, recognizes hypoxia 
response element (HRE) and activates the transcription of genes involved in hypoxia 
response, angiogenesis, etc. GLUT1 and VEGF are among those identified HIF-1 target 
genes that are crucially involved in adaption to hypoxia by switching nutrient utilization 
and turning on angiogenesis. 
A potential role for ERRs (including ERRα) in the hypoxic response was recently 
implicated by the demonstration of a direct interaction between ERR and HIF.  
Furthermore, overexpression of ERRs enhances HIF-mediated target gene transcription, 
while ERRs activity appears to be essential for the function of HIF. Both the expression 
of a dominant negative form of ERR and the treatment of a non-slective ERR inhibitor, 
diethylstilbestrol (DES) blocked the transcriptional activation of HIF target genes, such 
as VEGF, PGK1 and GLUT1 (Ao, Wang et al. 2008).   
Interestingly, VEGF, a well-characterized HIF-1 target gene, has also been shown 
to be upregulated by ERRα and its coactivator PGC-1α under normoxia conditions in a 
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HIF-independent manner (Arany, Foo et al. 2008, Stein, Chang et al. 2008, Klimcakova, 
Chenard et al. 2012). It is possible that the availability of HIF and/or PGC-1α determines 
how ERRα mediates the transcription of genes such as VEGF which contain both ERRE 
and HRE elements on their promoters. However, under hypoxia conditions when HIF is 
available, it is unknown whether ERRα still needs to be recruited to ERRE sites on the 
promoter, or it can be recruited by HIF protein via a tethering mechanism. 
3.1.3 Dissecting Canonical/Non-Canonical pathway of ERRα 
It is clear that ERRα is an important regulator of multiple biological and 
pathological processes. ERRα manifests these distinct activities by partnering with 
different cofactors and transcription factors.  A better understanding of the 
transcriptomes regulated by ERRα and its partners, and the mechanisms by these target 
genes are regulated will inform rationale design of ERRα modulators with favorable 
biological activities.  While the classical pathway of ERRα –mediated gene transcription 
is well-characterized, the mechanism of non-canonical ERRα pathways is still unclear. A 
key question is what role the direct DNA binding plays in non-canonical ERRα 
pathways.  As a first step toward dissecting the mechanistic differences between 
canonical and non-canonical pathways, we performed site-directed mutagenesis in 
ERRα DBD to abolish its DNA binding ability.   
It has been well-characterized that the residues in and around proximal (P-box) 
of the first zinc finger of the DBD domain are very important for DNA recognition and 
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binding. Mutations on the DNA recognition helix can cause alteration of DNA binding 
(Nguyen, Bail et al. 2007). Shown in Figure 3.1 is a model of the amino acid–base 
interactions underlying ER/ERE binding, where residues of Glu on position 2, Lys on 
position 5, Lys on position 9 and Arg on position 10 are involved in DNA binding. As 
shown in Table 3.1 and Figure 3.1, ERRα and ERα have great similarity in their DBD 
domain and P-Box sequences.  The goals of this study were to (1) identify target genes 
co-regulated by ERRα and HIF-1 that are of pathogenic importance in breast cancer and 
(2) dissect the mechanisms by which ERRα /HIF-1 co-regulate these genes. 
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Figure 3.1 DBD domains of ERα and ERRα 
A. DNA recognition helix of the estrogen receptor (ER). The position of amino acids in 
the DNA recognition helix is indicated by numbers from 1 to 13. Base-interacting 
residues in ERα are indicated in bold, and P box amino acids are underlined.  
B.  Models of the amino acid–base interactions underlying specific recognition of the 
estrogen response element by ER. Interactions considered in a proposed model (Suzuki 
and Yagi 1994) are in bold, while interactions described in the ER-ERE crystal structure 
(Schwabe, Chapman et al. 1993) but not in the model are in dashed lines.  
C. DBD domain of estrogen-related receptor alpha (ERRα) showing the two zinc fingers, 
proximal box (P-box) and distal box (D-box). Figure was adapted from publication on 
“Rational design of an estrogen receptor mutant with altered DNA-binding specificity” 
(Nguyen, Bail et al. 2007).  
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Table 3.1: P-Box and DNA response element sequences of nuclear receptors. 
 
 
  
 
Receptors DBD sequence near P-Box DNA response element 
ERR SCEACKAFFKR ERRE:  5’-TnAAGGTCA-3’ 
ER SCEGCKAFFKR ERE:             5’-AGGTCAnnnTGACCT-3’ 
AR/PR/GR  TCGSCKVFFKR GRE:             5’-AGAACAnnnTGTTCT-3’ 
TR TCEGCKGFFKR 
DR:               5’-AGGTCA-3’ 
RAR/ RXR  SCEGCKGFFKR 
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3.2 Materials and Methods 
3.2.1 Primers 
Mutagenesis primers were designed based on an siRNA resistant plasmid 
pcDNA_ERRαSiR, and the sequences for the forward primers are as follows: 
K104A: 5’- CAAAGCCTTCTTCGCGAGGACCATCCAGG -3’ 
R105A: 5’- CAAAGCCTTCTTCAAGGCGACCATCCAGGGGAG -3’ 
K104A/R105A:5’-CTGCAAAGCCTTCTTCGCGGCAACCATCCAGGGGAGCATC -3’ 
3.2.2 Plasmids 
Plasmids pcDNA_ERRα_K104A, pcDNA_ERRα_R105A and pcDNA _ ERRα _ 
K104A/R105A were constructed by site-directed mutagenesis PCR of pcDNA_ERRαsiR. 
Constructs of VP16_ERRα_K104A, VP16_ERRα_R105A and VP16_ERRα_K104A/R105A 
were made by cloning their coding sequeces from pcDNA constructs into VP16 vectors. 
Transcription reporters of 3xERE-TATA-luciferase, 5xGal4-luciferase and 
TOPFlash were previously described (Chang, Norris et al. 1999, Dwyer, Joseph et al. 
2010). HRE_luc reporter was purchased from Addgene (plasmid 26731). 
3.2.3 Cell culture 
HepG2 cells and Hela cells were obtained from American Type Culture 
Collection (Manassas, VA), expanded for two passages, and cryopreserved. Cells were 
cultured in Minimal Essential Medium (MEM) (Invitrogen) supplemented with 10% 
fetal bovine serum (HyClone, Logan, UT), 0.1 mM non‐essential amino acids and 1 mM 
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sodium pyruvate (Invitrogen) and maintained in a humidified 37°C incubator with 5% 
CO2. All experiments were performed with cells passaged less than 25 times. 
For cell transfections and mammalian two-hybrid assays, cells were switched to 
the less rich medium Basal Medium Eagle (BME) supplemented with 10% fetal bovine 
serum (HyClone, Logan, UT), 2 mM L-Glutamine, 0.1 mM non‐essential amino acids 
and 1 mM sodium pyruvate (Invitrogen). 
3.2.4 Transient transfections 
For transient transfections, HepG2 or Hela cells were seeded in wells of 96‐well 
plates 24 hours prior to transfection. On the day of transfection, the media was aspirated 
and cells were washed once with PBS. Cells were transfect using Lipofectin reagent 
(Invitrogen, Carlsbad, CA). Briefly, a DNA-Lipofectin mixture containing 600 ng of total 
plasmids per triplicate samples in 96‐well were mixed with Lipofectin® in OptiMEM 
according to manufacturer’s protocol (Invitrogen). Cells in each well were transfected 
with 10 μl DNA-lipofectin mixture. After indicated hours, transfected cells were 
harvested, when luciferase and β-galactosidase (β-gal) activities were measured using a 
Fusion™ Universal Microplate Analyzer (PerkinElmer). Each experiment was repeated 
at least three times. Representative results are presented as standard luciferase activity 
normalized with β-Gal for transfection efficiency, ± standard error of the mean (SEM) 
per triplicate samples. 
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3.2.5 RNA preparations and analysis 
Total RNA of cell culture was isolated using the Bio-Rad Aurum RNA 
purification kit. 0.5 μg of isolated total RNA was used to synthesize cDNA using iScript 
cDNA synthesis kit (BioRad). Real-time PCR was performed using CFX384 Real-Time 
System (BioRad) with 0.06 μl cDNA, 0.3 μM primers and iQ SYBRGreen supermix 
(BioRad). cDNA was quantified using the 2-ΔΔCt method (Livak and Schmittgen 2001). 
Data was normalized to either 36B4 or RSP18 internal controls. Cell culture data is 
representative of three independent experiments, while tumor data is the mean ± SEM. 
 
3.3 Results 
3.3.1 Overlap between ERRα and HIF-1 target genes 
It was reported in a previous study that ERRα and HIF physically interact with 
each other and coregulate a handful of known HIF target genes. To assess the extent of 
the crosstalk between these transcription factors, we performed a preliminary 
examination of available ChIP and microarray datasets to identify genes that can 
potentially be regulated by both ERRα and HIF. HIF target genes were culled from a 
ChIP-ChIP analysis performed in MCF7 cells using either HIF-1α or HIF-2α antibodies. 
(Mole, Blancher et al. 2009). ERRα target genes were obtained from a MCF7 microarray 
analysis previously performed in our lab using PGC-1α to activate ERRα. Genes that are 
either up- or down- regulated by PGC-1α were included in this analysis (Stein, Chang et 
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al. 2008). We found a very small overlap of target genes; 62 of the 397 genes bound by 
HIF-1α and 41 of the 131 genes bound by HIF-2α were found to be ERRα-regulated 
(Table 3.2). 
Unexpectedly, among these selected target genes of HIF, most of them are 
actually downregulated by the overexpression of the ERRα coactivator, PGC-1α. We 
have tested a few genes on this list. However, while most of the genes we tested could 
be induced by hypoxia or hypoxia mimetics in MCF7 and MDA-MB-231 cells, the 
treatment of siERRα or ERRα antagonists had minor effects on the induction. We were 
unable to recapitulate the observations made by Ao et al., as we found no repression of 
PGK-1 induction by siERRα or ERRα antagonists. This could be due to differences in cell 
line models or treatment conditions.  Because we were interested in target genes that are 
robustly co-regulated by HIF-1 and ERRα in multiple cell lines, as an alternative we 
turned to the literature to identify well-characterized HIF-1 target genes and tested the 
effect of ERRα on the regulation of these genes. Using this methodology, we found a 
well-known HIF-1 target gene, CA9, to be coregulated by ERRα and HIF-1. 
 
. 
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Table 3.2: Overlap of ERR and HIF target genes. 
HIF regulated genes were detected in MCF7 cells treated with 2 mM 
dimethyloxalylglycine (DMOG) using ChIP-ChIP analysis of HIF-1α and HIF-2α 
binding (Mole, Blancher et al. 2009).  ERRα regulated genes were identified by 
microarray analysis of MCF7 cells with PGC-1α overexpression (Stein, Chang et al. 
2008). PGC-1α upregulated genes are defined as those with more than 2-fold increase, 
while PGC-1α downregulated genes are those with more than 50% decrease. 
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HIF-1/2α HIF-1α HIF-2α 
PGC1α 
upregulated 
COX7C FAM162A MFN2 
ID2 GLRX 
 KDM3A (JMJD1A) IQCG 
 PLEKHA6 NDUFA5 
 
 
RAPGEF6 
 
 
UQCRC2 
 
PGC1α 
downregulated 
BAMBI ANXA2 AGR2 
C7orf68 (HIG2) ATP9A BMP4 
CHD1L BBX CPOX 
GPRC5A BRIP1 DRAM1 
HK2 C15orf39 ERO1L 
IER3 CARHSP1 IGF1R 
LOXL2 CYP24A1 IL6R 
NFIL3 ENO2 KRT18 
PAICS HJURP KRT8 
RAP2B MXI1 PFN2 
SAP30 MYC PLAC8 
SNAPC1 NBPF10 S100A4 
SPRY1 RPL10 
 TMEM97 TGIF1 
 ZMYND8 TRIM33 
 
 
NBPF10 
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3.3.2 ERRα is involved in CA9 transcription 
Carbonic anhydrases are a family of zinc metalloenzymes that catalyze the 
reversible hydration of carbon dioxide to bicarbonate and protons: 
  
They participate in a variety of biological processes, including respiration, 
calcification, acid-base balance, bone resorption, the formation of aqueous humor, 
cerebrospinal fluid, saliva, and gastric acid. Members in the family have extensive 
diversity in tissue distribution and subcellular localization (Chegwidden and Carter 
2000, Supuran 2008). 
Carbonic anhydrase 9 (CA9) is a membrane-associated member in the family 
with extracellular carbonic anhydrase activity. It is a clinical indicator of aggressive 
breast, bone and lung cancer (Chia, Wykoff et al. 2001, Giatromanolaki, Koukourakis et 
al. 2001, Generali, Fox et al. 2006). CA9 expression is most notably induced by hypoxia 
conditions under the regulation of hypoxia-inducible factor 1 alpha (HIF-1α), and is an 
established marker of tumor hypoxia. 
To test the influence of modulating ERRα on HIF-1 transcriptional activity, we 
first performed a combination treatment of ERRα antagonists and hypoxia mimetics that 
stabilize HIF-1α. As shown in Figure 3.2, the treatment of HIF-1α stabilizers (CoCl2 or 
DFO) robustly induced the transcription of CA9. However, the addition of ERRα 
antagonists (XCT790 or Compound A) dampened the induction of CA9 transcription. 
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Consistently, knocking down ERRα expression by siRNA has similar effect on CA9 
induction, as shown in Figure 3.3. Not only does ERRα expression level affect the 
function of the HIF-1α mimetics, CoCl2, DFO and DMOG, it also affects hypoxia induced 
CA9 expression. As shown in Figure 3.4, the induction of CA9 by low oxygen conditions 
(either 5% or 0% oxygen) is reduced by ERRα knockdown. Interestingly, overexpression 
of the ERRα coactivator PGC-1α has no effect on CA9 induction (Figure 3.5), suggesting 
a PGC-1α independent function of ERRα in the regulation of CA9. This is clearly 
different from the transcriptional regulation of VEGF, where both low oxygen and PGC-
1α overexpression induced VEGF. 
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Figure 3.2 ERRα antagonists decrease CA9 induction by HIF-1α stabilizer 
SKBR3 cells were seeded in wells of 6‐well plates. To manipulate ERRα activity, 
cells were treated with 10 μM XCT790, 10 μM Compound A, or DMSO vehicle. To 
stabilize HIF-1α, cells were treated with 100 μM CoCl2 or 100 μM DFO. Cells were 
treated for 17 hours, and harvested. Representative result shows the qPCR analysis of 
CA9 mRNA levels normalized to 36B4 and represented as mean ± SEM of triplicate 
wells. 
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Figure 3.3 ERRα siRNA decreases CA9 induction by HIF-1α stabilizer 
MCF7 cells were seeded in wells of 12‐well plates. To knockdown ERRα, cells 
were transfected with siRNAs targeting ERRα, either siERRαA or siERRαB. Siluc and 
siMed were two negative controls. A mock transfection was also included as a control. 
48 hours after transfection, cells were treated with 100 μM CoCl2, 250 μM DFO or 100 
μM DMOG. Cells were harvested 8 hours after treatment. Representative result shows 
the qPCR analysis of CA9 mRNA levels normalized to 36B4 and represented as mean ± 
SEM of triplicate wells. 
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Figure 3.4 ERRα siRNA decreases CA9 induction by hypoxia 
MCF7 cells were seeded in wells of 12‐well plates. To knockdown ERRα, cells 
were transfected with siRNAs targeting ERRα, either siERRαA or siERRαB. Siluc and 
siMed were two negative controls. A mock transfection was also included as a control. 
48 hours after transfection, cells were moved to hypoxia chamber with 0% or 5% O2. 
Cells were harvested after overnight hypoxia treatment. Representative result shows the 
qPCR analysis of CA9 mRNA levels normalized to 36B4 and represented as mean ± SEM 
of triplicate wells.  
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Figure 3.5 PGC-1α overexpression has no effect on CA9 induction by hypoxia 
MCF7 cells were seeded in wells of 6‐well plates. Cells were infected with 
adenoviruses β-galactosidase (βgal), wild-type PGC-1α (WT), PGC-1α 2X9 mutant (2X9) 
or PGC-1α L2L3M mutant (L2L3M) as indicated. 48 hours after infection, cells were 
moved to hypoxia chamber with 0% or 5% O2. Cells were harvested after overnight 
hypoxia treatment. Representative result shows the qPCR analysis of CA9 mRNA levels 
normalized to 36B4 and represented as mean ± SEM of triplicate wells. 
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3.3.3 Controversial role of ERRα on HIF-1 transcription 
While ERRα is previously reported to stimulate HIF-induced transcription (Ao, 
Wang et al. 2008) , to our surprise, we found that the expression of ERRα shows a dose-
dependent repression of HIF-1 transcriptional activity in Hela cells. Hela cells were 
transfected with HRE_luc reporter, the transcription of which was activated by the 
addition of CoCl2, a compound which mimics hypoxic stimulus and stabilizes HIF-1α. 
Meanwhile, cells were also transfected with various amount of pcDNA_ERRα plasmid. 
As shown in Figure 3.6, the addition of 50 ng and 100 ng of ERRα expression plasmid 
clearly reduced the luciferase gene expression of the reporter, while no enhancement of 
transcription was seen for any dose of ERRα expression. Similar effect was also seen for 
ERRβ expression. 
It is possible that the ERR proteins expressed were not functionally active on the 
promoter of the HRE_luc reporter, which may need activation by coactivators. Thus, we 
modified the experimental settings and included the expression of the ERRα coactivator 
PGC-1α. Again, surprisingly, the addition of the PGC-1α expression plasmid did not 
promote, but suppressed, the transcription of HIF reporter gene (Figure 3.7). 
Because HIF-1α protein level is a key determinant of hypoxia-mediated target 
gene transcription, we wanted to determine if ERRα and PGC-1α affect HIF-1 mediated 
gene transcription by indirectly affecting HIF-1α protein level. SKBR3 cells were treated 
with ERRα antagonists for 8 hours before CoCl2 treatment. We were surprised to find 
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that XCT790 but not compound A reduced the protein level of HIF-1α (Figure 3.8).  It 
remains to be determined whether XCT790 affects HIF-1α at the level of transcription, 
translation, or protein stability.  . At this point, it is unclear if the dramatic down 
regulation of HIF-1 reporter gene with PGC-1a overexpression is due to down 
regulation of the HIF-1 protein, an experiment worth testing in the future. 
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Figure 3.6 ERRα decreases HIF-1 transcriptional activity on HRE_luc reporter 
Hela cells were seeded in wells of 96‐well plates 24 hours prior to transfection. 
For triplicate wells, plasmid DNA containing 300 ng HRE_luc, 20 ng pCMV B-GAL and 
indicated amount of pcDNA_ERRα or pcDNA_ERRβ was normalized to a total of 600 
ng DNA with pBSII. The plasmid DNA was mixed with Lipofectin® in OptiMEM. Cells 
in each well were transfected with 10 μl DNA-lipofectin mixture. After 2 hours of 
transfection, cells were treated with 100 μM CoCl2 to stabilize the HIF-1α protein. Non-
treated samples were included as negative controls. After 20 hours of treatment, cells 
were harvested, when luciferase and β-galactosidase (β-gal) activities were measured 
using a Fusion™ Universal Microplate Analyzer (PerkinElmer). Each experiment was 
repeated at least three times. Representative results are presented as standard luciferase 
activity normalized with β-Gal for transfection efficiency, ± standard error of the mean 
(SEM) per triplicate samples. 
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Figure 3.7 PGC-1α decreases HIF-1 transcriptional activity on HRE_luc reporter 
Hela cells were seeded in wells of 96‐well plates 24 hours prior to transfection. 
For triplicate wells, plasmid DNA containing 300 ng HRE_luc, 20 ng pCMV B-GAL, 100 
ng pcDNA_PGC1α_2X9 and indicated amount of pcDNA_ERRα or pcDNA_ERRβ was 
normalized to a total of 600 ng DNA with pBSII. The plasmid DNA was mixed with 
Lipofectin® in OptiMEM. Cells in each well were transfected with 10 μl DNA-lipofectin 
mixture. After 2 hours of transfection, cells were treated with 100 μM CoCl2 to stabilize 
the HIF-1α protein. Non-treated samples were included as negative controls. After 20 
hours of treatment, cells were harvested, when luciferase and β-galactosidase (β-gal) 
activities were measured using a Fusion™ Universal Microplate Analyzer 
(PerkinElmer). Each experiment was repeated at least three times. Representative results 
are presented as standard luciferase activity normalized with β-Gal for transfection 
efficiency, ± standard error of the mean (SEM) per triplicate samples. 
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Figure 3.8 Effect of ERRα antagonists on HIF-1α protein level in SKBR3 cells 
XCT790, but not compound A, reduces the protein level of HIF-1α stabilized by 
CoCl2. SKBR3 cells were treated with ERRα antagonists for 8 hours, including 10 μM 
XCT790, 10 μM Compound A or DMSO vehicle prior to treatment with 100 μM CoCl2 
for 16 hours.  Western blot analysis of HIF-1α, ERRα and GAPDH loading control was 
performed to harvested protein samples. 
HIF-1α
ERRα
GAPDH
DMSO XCT Compound A
-- CoCl2 -- CoCl2 -- CoCl2
Figure 3. Effect of ERRα antagonists on ERRα
and HIF-1α protein level in SKBR3 cells
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3.3.4 DBD mutants as a tool to study non-canonical role of ERRα 
It is clear from studies of our own and others’ that part of the ERRα biology is 
attributable to its crosstalk with other signaling transduction pathways such as Wnt-
signaling and the hypoxia response. However, the molecular mechanism(s) by which 
ERRα interacts with these transcription factors on target gene promoter to activate 
transcription is still not clear. 
Figure 3.9 depicts our proposed model of ERRα canonical and non-canonical 
transcriptional regulation. Different mechanisms may get involved in the transcriptional 
activities of ERRα. The canonical pathway is shown on the right, where ERRα directly 
recognizes ERRE and recruits coactivators like PGC-1α for transcriptional regulation. 
The non-canonical pathway is shown on the left, where ERRα can physically interact 
with transcriptional factors such as the hypoxia inducible factor 1 heterodimer (HIF-
1α/β), or transcriptional cofactors such as β-catenin (β-cat) to regulate gene transcription. 
Whether direct binding to DNA is necessary for ERRα non-canonical pathway remains 
unknown. 
The most obvious way to distinguish between direct ERRE binding versus a 
tethering mechanism is to mutate the ERRα DBD so that it is not able to bind DNA.  
Although a crystal structure of ERRα DBD is not yet available, the DNA binding 
domains of other NRs have been characterized extensively. Since ERRα and ERα shared 
the highest degree of structural and sequence homology in their DNA binding domains, 
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the DNA binding requirement of ERRα DBD can be inferred from what is known for 
ERα (Jakacka, Ito et al. 2001). Upon activation by estrogens, ERα dimerizes and binds 
directly to estrogen response elements (EREs) to regulate gene transcription.  In 
addition, ERα can also regulate the transcription of AP1 target genes through a non-
classical mechanism. The effects of ERα DBD mutations were examined in DNA binding 
assays using reporter constructs containing either EREs (classical) or AP1 (nonclassical) 
response elements. DBD mutations in the proximal (P-box) of the first zinc finger of the 
ERα (E207A/G208A and E207G/G208S) eliminated ERE binding. While these mutants 
were inactive on the ERE reporter, they retained partial or full activity on AP1 reporter, 
suggesting DNA binding is not required for ERα activity through the non-classical AP1 
pathway.  
It is possible that ERRα can adopt a similar mode in its transcription regulation. 
To test the hypothesis that ERRα non-canonical pathway involves ERRα interactions 
with other proteins rather than direct binding to DNA, we introduced mutations into the 
DNA binding domain (DBD) of ERRα. Based on the residues on ERα known to be 
important for the formation of ERα/ERE protein/DNA complex, we chose residues 
Lysine 104 and Arginine 105 on ERRα for mutation.  
To characterize these ERRα mutants, a transcriptional assay was performed. Hela 
cells were transfected with ERRα reporter gene 3xERE_luc, the transcriptional of which 
can be induced by ERRα expression. As shown in Figure 3.10, DBD mutation on Lysine 
 75 
104, Arginine 105, or both sites, indeed abolishes the transcriptional activity of ERRα on 
3xERE_luc reporter.   
The DNA binding of these mutants was examined by a mammalian one-hybrid 
assay. As shown in Figure 3.11, the loss of function observed in Figure 3.9 could be 
largely due to the incapability of the mutants to bind DNA response element. While 
K104A mutant still retains a weak binding to ERE, the R105A mutant completely loses 
the binding affinity to ERE. 
To evaluate the AF2 coactivator binding ability of these DBD mutants, a 
mammalian two-hybrid assay was performed to test the interaction between ERRα DBD 
mutants and PGC1α_L3 peptide, a fragment from the third LXXLL motif of PGC-1α. As 
shown in Figure 3.12, ERRα wild-type, K104A mutant, R105A mutant and the double 
site mutant all exhibit similar binding to PGC1α_L3 peptide. Thus, we successfully 
constructed ERRα DBD mutants that lose ERE-binding but retain ability to interact with 
coactivators in the AF2 domain. 
Initially, these DBD mutants were aimed at separating canonical and non-
canonical pathways of ERRα. However, our study found that the DBD is required for 
both canonical and non-canonical target genes. As shown in Figure 3.13, when cells were 
transfected with the TOPFlash reporter, the transcription was synergistically 
upregulated by β-cat and ERRα. However, the upregulation by ERRα was completely 
abolished by ERRα DBD mutations. In a similar manner, the repression of HRE_luc 
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reporter gene by ERRα was also demolished by DBD mutations on ERRα (Figure 3.14). 
To rule out the possibility that the effects seen were due to a variance in expression 
levels, western blot analysis confirmed that all mutants were expressed at the same level 
(data not shown). Clearly the intact DBD domain is required for ERRα activity on these 
reporters.  
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Figure 3.9 Model of ERRα canonical and non-canonical transcriptional activities 
Depicted is an updated model showing how different mechanisms may get 
involved in the transcriptional activities of ERRα. The canonical pathway is shown on 
the right, where ERRα directly recognizes ERRE and recruits coactivators like PGC-1α 
for transcriptional regulation. The non-canonical pathway is shown on the left, where 
ERRα can physically interact with transcriptional factors such as hypoxia inducible 
factors 1 heterodimer (HIF-1α/β), or transcriptional cofactors such as β-catenin (β-cat) to 
regulate gene transcription.
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Figure 3.10 ERRα DBD mutants abolish activity on 3xERE reporter 
Hela cells were seeded in wells of 96‐well plates 24 hours prior to transfection. For 
triplicate wells, plasmid DNA containing 300 ng 3xERE_luc, 20 ng pCMV B-GAL and 10 
ng of pcDNA or pcDNA_ERRα (either wild type or DBD mutants) was normalized to a 
total of 600 ng DNA with pBSII. The plasmid DNA was mixed with Lipofectin® in 
OptiMEM. Cells in each well were transfected with 10 μl DNA-lipofectin mixture. After 
48 hours of transfection, cells were harvested, when luciferase and β-galactosidase (β-
gal) activities were measured using a Fusion™ Universal Microplate Analyzer 
(PerkinElmer). Each experiment was repeated at least three times. Representative results 
are presented as standard luciferase activity normalized with β-Gal for transfection 
efficiency, ± standard error of the mean (SEM) per triplicate samples
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Figure 3.11 ERRα DBD mutants abolish DNA binding activity 
To test the DNA binding activity of ERRα DBD mutants, “mammalian one-
hybrid” assay was performed. HepG2 cells were seeded in wells of 96‐well plates 24 
hours prior to transfection. For triplicate wells, plasmid DNA containing 300 ng 
3xERE_luc, 20 ng pCMV B-GAL and 100 ng of VP16 or VP16_ERRα (either wild type or 
DBD mutants) was normalized to a total of 600 ng DNA with pBSII. The plasmid DNA 
was mixed with Lipofectin® in OptiMEM. Cells in each well were transfected with 10 μl 
DNA-lipofectin mixture. After 48 hours of transfection, cells were harvested, when 
luciferase and β-galactosidase (β-gal) activities were measured using a Fusion™ 
Universal Microplate Analyzer (PerkinElmer). Each experiment was repeated at least 
three times. Representative results are presented as standard luciferase activity 
normalized with β-Gal for transfection efficiency, ± standard error of the mean (SEM) 
per triplicate samples.  
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 Figure 3.12 ERRα DBD mutants retain ability to interact with PGC-1α fragment 
To test ability of ERRα DBD mutants to interact with PGC1α_L3 peptide, a 
fragment from the third LXXLL motif of PGC-1α, mammalian two-hybrid assay was 
performed. HepG2 cells were seeded in wells of 96‐well plates 24 hours prior to 
transfection. For triplicate wells, plasmid DNA containing 180 ng 5xGal4-luciferase, 20 
ng pCMV B-GAL, 200 ng of pM or pM_PGC1aL3, 200 ng of VP16 or VP16_ERRα (either 
wild type or DBD mutants) was normalized to a total of 600 ng DNA with pBSII. The 
plasmid DNA was mixed with Lipofectin® in OptiMEM. Cells in each well were 
transfected with 10 μl DNA-lipofectin mixture. After 48 hours of transfection, cells were 
harvested, when luciferase and β-galactosidase (β-gal) activities were measured using a 
Fusion™ Universal Microplate Analyzer (PerkinElmer). Each experiment was repeated 
at least three times. Representative results are presented as standard luciferase activity 
normalized with β-Gal for transfection efficiency, ± standard error of the mean (SEM) 
per triplicate samples.  
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Figure 3.13 ERRα DBD mutants lose transactivation on TOPFlash reporter 
Hela or HepG2 cells were seeded in wells of 96‐well plates 24 hours prior to 
transfection. For triplicate wells, plasmid DNA containing 300 ng TOPFlash reporter, 20 
ng pCMV B-GAL, 12 ng pCAN_deleN_Bcat (or pcDNA control) and indicated amount 
of pcDNA or pcDNA_ERRα (either wild type or DBD mutants) was normalized to a 
total of 600 ng DNA with pBSII. The plasmid DNA was mixed with Lipofectin® in 
OptiMEM. Cells in each well were transfected with 10 μl DNA-lipofectin mixture. After 
48 hours of transfection, cells were harvested, when luciferase and β-galactosidase (β-
gal) activities were measured using a Fusion™ Universal Microplate Analyzer 
(PerkinElmer). Each experiment was repeated at least three times. Representative results 
are presented as standard luciferase activity normalized with β-Gal for transfection 
efficiency, ± standard error of the mean (SEM) per triplicate samples.
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Figure 3.14 ERRα DBD mutants lose suppressive activity on HRE_luc reporter 
Hela cells were seeded in wells of 96‐well plates 24 hours prior to transfection. For 
triplicate wells, plasmid DNA containing 300 ng HRE_luc reporter, 10 ng pCMV B-GAL, 
100 ng of pcDNA or pcDNA_ERRα (either wild type or DBD mutants) was normalized 
to a total of 600 ng DNA with pBSII. The plasmid DNA was mixed with Lipofectin® in 
OptiMEM. Cells in each well were transfected with 10 μl DNA-lipofectin mixture. After 
2 hours of transfection, cells were treated with 100 μM CoCl2 to stabilize the HIF-1α 
protein. Non-treated samples were included as negative controls. After 20 hours of 
treatment, cells were harvested, when luciferase and β-galactosidase (β-gal) activities 
were measured using a Fusion™ Universal Microplate Analyzer (PerkinElmer). Each 
experiment was repeated at least three times. Representative results are presented as 
standard luciferase activity normalized with β-Gal for transfection efficiency, ± standard 
error of the mean (SEM) per triplicate samples. 
 
 83 
3.4 Discussion 
One of the primary issues we sought to address in this study was how ERRα 
modulates its non-canonical pathways, which mainly focused on understanding the 
mechanism(s) of ERRα/HIF-1cross talk. It’s known that NRs collaborate with various 
other signaling pathways to regulate target gene transcription.  For example, the wnt/β-
cat signaling pathway has been shown to cross talk with a variety of NRs, such as 
androgen receptor (AR), retinoid X receptor (RXR), Liver receptor homolog-1 (LRH-1) 
(Mulholland, Dedhar et al. 2005). β-cat serves as an AR coactivator in regulating 
endogenous AR target genes such as PSA (Taplin, Rajeshkumar et al. 2003). Cross talk 
between the Wnt pathway and LRH-1 induces cell proliferation through the 
concomitant induction of cyclin D1 and E1 One of the primary issues we sought to 
address in this study was to determine how ERRα modulates its non-canonical 
pathways, which mainly focused on understanding the mechanism(s) of ERRα/HIF-
1cross talk. It is known that NRs collaborate with various other signaling pathways to 
regulate target gene transcription.  For example, the Wnt/β-cat signaling pathway has 
been shown to cross talk with a variety of NRs, such as androgen receptor (AR), retinoid 
X receptor (RXR), Liver receptor homolog-1 (LRH-1) (Mulholland, Dedhar et al. 2005). β-
cat serves as an AR coactivator in regulating endogenous AR target genes such as PSA 
(Taplin, Rajeshkumar et al. 2003). Cross talk between the Wnt pathway and LRH-1 
induces cell proliferation through the concomitant induction of cyclin D1 and E1 
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(Botrugno, Fayard et al. 2004). It is therefore not surprising that we and others have 
found that ERRα is also able to interact and crosstalk with other signaling pathways.  
We have previously reported the crosstalk between ERRα and Wnt-signaling pathways, 
which cooperate in the regulation of cell migration. ERRα has also been shown to be 
involved in the hypoxia response through direct interaction with HIF-1.  We are 
particularly interested in these two pathways because of their relevance to cancer.  
Previous studies used a candidate gene approach to characterize the crosstalk. In this 
study, we used a bioinformatics analysis with the goal of identifying additional target 
genes/pathways that are the results of ERRα/HIF-1 crosstalk.  In this manner, we 
identified 54 putative ERRα/HIF-1 coregulated genes (Table 3.2). However, qPCR 
analysis failed to confirm most of the genes identified to be HIF-1/ERRα coregulated. 
The reason could be that the genes regulated by PGC-1α/ERRα may not have ERRα 
involved when regulated by HIF-1. 
As an alternative to the bioinformatics analysis, we also used a candidate gene 
approach and identified CA9 as a gene that is coregulated by ERRα and HIF. CA9 is an 
interesting target gene in signaling, given its role in maintaining the intracellular / 
extracellular pH balance and its association with cancer. The regulation of CA9 suggests 
ERRα may be involved in coping with the acidic environment of tumor. Importantly, we 
identified that CA9 is regulated by ERRα/HIF in a PGC-1α independent manner.  
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It is clear that ERRα can crosstalk with other signaling pathways. However, the 
mechanism(s) and molecular basis behind these pathways are still unclear. To address 
the first model (direct DNA binding of ERRα), we asked whether the genes coregulated 
by ERRα and HIF-1 or βcat contain any ERRE for potential ERRα binding. Our lab had 
previously performed a preliminary examination of available ChIP-ChIP and ChIP-seq 
datasets. A small but significant overlap were found between genes with enriched ERRα 
binding in MCF7 or SKBR3 breast cancer cells and genes with enriched β-catenin 
binding in HCT116 colon cancer cells. Also, bioinformatics analyses using Patser 
revealed that out of the 988 β-catenin target genes identified in the HCT116, 
approximately 17% of the genes also contain at least one putative ERRα binding site 
within 600-bp region of DNA enriched for β-catenin binding (Dwyer, Joseph et al. 2010).  
This suggests that it is possible for direct ERE binding to be involved in the ERRα/β-cat 
signaling. However, for the ERRα/HIF signaling, no dataset for ERRα under hypoxia or 
hypoxia mimic condition is available. Instead, we compared the genes identified with 
the HIF stabilizer DMOG and genes regulated by ERRα coactivator PGC-1α 
overexpression in MCF7 cells. Using this method, we found some HIF target genes that 
can also be regulated by PGC-1α. Surprisingly, most of these genes are down-regulated 
by PGC-1α under normoxia. However, with a few genes tested by qPCR analysis, we 
were unable to validate if they are co-regulated by PGC-1 and HIF-1. The opposing roles 
of HIF and PGC-1α may be explained by their physiological stimuli: while HIF is an 
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oxygen stress sensor, PGC-1α is a metabolic stress sensor. Thus, it is possible that PGC-
1α copes with the need to meet high-energy demand, such as upregulating 
mitochondria function, while HIF copes with low oxidation and suppresses 
mitochondria function. 
In addition to mechanisms described in the first model, ERRα can also regulate 
target gene transcription by tethering to other transcription factors (Model 2).  Because it 
has been previously shown that ERRα and HIF-1 can physically interact to enhance HIF-
1 mediated target gene transcription, we wanted to confirm this observation using a 
simple reporter gene assay. Surprisingly, our transcriptional assay revealed that both 
ERRα and PGC-1α expression decreased the transcription of HRE_luc reporter, a 
widely-used reporter for HIF activity. This reporter contains three hypoxia response 
elements (24-mers) from the Pgk-1 gene upstream of firefly luciferase. It is possible that 
the presence of ERRE sites is also necessary for ERRα to be recruited in an “active” state 
for ERRα/HIF signaling. Without binding sites for ERRα on the promoter, the interaction 
between ERRα and HIF may block HIF and cofactor recruitment, thus dampen the 
transcription.  
In an attempt to further probe the tethering mechanism, ERRα DBD mutants 
were used as a tool to define the molecular mechanism for ERRα/β-cat and ERRα/HIF 
signaling. Our finding suggests that ERRα DBD is important for the receptor to 
influence β-cat and HIF transcriptional activity. It is likely that the DNA binding of 
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ERRα on potential ERRE sites of the promoters is necessary for the receptor to potentiate 
the transcription. However, our results do not preclude the possibility that the mutated 
residues in DBD are involved in the protein- protein interaction of ERRα/β-cat or 
ERRα/HIF, thus the mutants abolished the effect of ERRα on these pathways. In the 
future, a CoIP assay could be used to test whether these ERRα DBD mutants can still 
interact with β-cat and HIF-1. 
For future work, whole genome studies, such as ChIP-chip and CHIP-seq, will 
enable an evaluation of the extent to which HIF and ERRα binding sequences overlap in 
endogenous genes under hypoxia conditions and the relative importance of this 
mechanism of receptor crosstalk. 
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Chapter 4  Probing structure of ERRα using M13 phage 
display 
4.1 Introduction 
Estrogen-related receptors (ERRs) are orphan members of the nuclear receptor 
superfamily, which include ERRα, ERRβ and ERRγ. So far, no known natural ligand has 
been identified that could bind ERRs. The folding of α-helices and β-sheets of the C-
terminus of a nuclear receptor forms a ligand binding cavity, its volume and the amino 
acid residues lining the pocket determine the ligand recognition. Unlike some steroid 
receptors with large volume of ligand binding pocket (ERα ~450 Å3, GR ~600 Å3), 
(Brzozowski, Pike et al. 1997, Bledsoe, Montana et al. 2002), the cavities of ERRs are very 
small. The volume of ERRγ ligand binding pocket is 220 Å3 (Greschik, Wurtz et al. 2002), 
while that of ERRα is even smaller, only 100 Å3. While the sequences of ERRα and ERRγ 
in ligand binding domain (LBD) are very similar, ERRα LBD contains a phenylalanine 
(Phe 232), whose side chain largely fills the cavity and blocks potential binding of a 
natural ligand (Kallen, Schlaeppi et al. 2004). That said, several synthetic ligands have 
been identified for the ERRs and their binding to the ligand binding pockets of ERRα 
and ERRγ have been confirmed by crystallography studies (Greschik, Flaig et al. 2004, 
Kallen, Lattmann et al. 2007). 
Although no natural ligand has been identified for ERRα, several classes of 
synthetic ERRα antagonists have been developed. For example, XCT790 (or XCT for 
short) is an ERRα antagonist that blocks its transcriptional activity of ERRα and also 
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causes degradation of the receptor (Busch, Stevens et al. 2004). Compound A, on the 
other hand, only interferes with the transcriptional activity of ERRα but is without an 
effect on the receptor protein level (Chisamore, Mosley et al. 2008). Besides the 
differences on ERRα stability, these two antagonists also exert different effects on cancer 
cells. Previously our lab has shown that although both compounds inhibited cell 
proliferation, only the ERRα degrader XCT790 reduced cell migration, while compound 
A was without an effect in this assay.  
It has been well established that NRs depend on interactions with specific 
transcriptional coregulators to regulate distinct biological processes. In general, 
recruitment of coactivators facilitates the assembly of a large protein complex, which 
acetylates chromatin and engages general transcription machinery to enhance 
transcription initiation and elongation of target genes.  Recruitment of co-repressor 
proteins, on the other hand, deacetylates chromatin and shuts down transcription. 
Furthermore, it has been demonstrated that different ligands can induce distinct 
receptor conformations and thereby facilitate the differential recruitment of functionally 
distinct coregulators. Therefore, NRs could manifest different biological activity 
depending on their conformational states induced by ligands and relative expression 
levels of cellular cofactors. This type of activity is exemplified by the selective estrogen 
receptor modulators (SERMs), such as tamoxifen.  Tamoxifen is widely used in the 
treatment of ER positive breast cancer for its ER antagonist activity in the breast; 
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however it functions as an ER agonist in the uterus and bone. Much of the resistance 
observed in the clinic to tamoxifen endocrine therapy was attributable to its partial 
agonist activity and, therefore, pure antagonists, such as fulvestrant, which degrade the 
receptor are highly desirable for oncological use.  By extrapolation, we propose that 
ERRα degraders such as XCT790 will antagonize all aspects of ERRα function, while 
non-degrading antagonists like compound A may actually function in a selective 
manner, much as the SERMs do on ERα. The balance between complete and partial 
antagonism depends on the spectrum of biological functions the receptor is involved in 
and the proposed indications of the ligands.  Therefore, a better understanding of the 
molecular basis of the antagonism of ERRα ligands would facilitate the development of 
compounds that exhibit favorable biological activities. 
At the onset of this study, no structural information was available for antagonists 
that bind to ERRs. Whether XCT and Compound A manipulate the receptor in similar 
manners or not was unknown. Given the relatively small ligand binding pocket in the 
Apo-ERRα, it is possible that binding of an antagonist would force the receptor to 
undergo global conformational changes. It is also possible that some ERRα antagonists 
may bind regions other than the canonical ligand-binding pocket, as is currently being 
investigated for ligands of the androgen receptor. Understanding how antagonists alter 
ERRα structure is important. Not only because such information could help explain the 
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functional differences between different classes of antagonists, it will be instructive in 
the development of novel ERRα inhibitors. 
In the current study, we screened for small peptides that can interact with ERRα 
in Apo, XCT-bound, and Compound A-bound forms using M13 phage display. These 
peptides served as surface probes for ERRα structures. This chapter details the 
purification of full-length ERRα as well as the validation and characterization of the 
small peptides identified.  
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4.2 Materials and Methods  
4.2.1 Plasmids 
The construction of pcDNA3-ERRα, VP16-ERRα and 5xGal4-luciferase plasmids 
was described previously (Chang, Norris et al. 1999, Stein, Gaillard et al. 2009).  All the 
pM5.1_peptide plasmids to express Gal4DBD-peptide fusions were constructed as 
follows: DNA sequences coding for the peptides were PCR amplified from the M13 
phage,  digested with Xba I and Xho I and subcloned into the pM5.1 vector (modified 
from pM, Clontech) (Mettu, Stanley et al. 2007) . All PCR products were sequenced to 
ensure the fidelity of the resulting constructs. 
4.2.2 Production and purification of recombinant ERRα 
The construction of baculovirus for ERRα production has been previously 
described in the lab (Gaillard, Grasfeder et al. 2006). Briefly, the full-length ERRα cDNA 
was subcloned into a modified baculovirus shuttle vector pDW464-rTEV (Chang, Norris 
et al. 1999) to generate a fusion of ERRα with a biotin acceptor peptide (BAP) linked by a 
recombinant tobacco etch virus (rTEV) protease cleavage site. The recombination of this 
plasmid with the baculovirus genome resulted in recombinant baculoviral DNA, which 
could be transfected into Spodoptera frugiperda (Sf9) cells to produce baculovirus.  
Sf9 cells were maintained in serum-free SFX media (Hyclone) in a 27°C incubator 
shaking at 245 rpm. Sf9 cell culture density was maintained between 0.5~8x106 cells /ml 
for best cell growth. (The doubling time of Sf9 was measured to be around 20 hours.) At 
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the log-phase (cell density around 2x106 cells /ml), Sf9 cells were centrifuged at 900rpm, 
re-suspended in fresh SFX media to reach 2x106 cells /ml, and infected with 1-5 MOI of 
ERRα baculovirus. After 48-hour infection, Sf9 cells were harvested. Cell culture 
supernatant was collected as new baculovirus stock and kept at 4°C. Cell pellets were 
washed once with ice-cold PBS, frozen in liquid nitrogen and stored at -80°C.  
To extract the biotinylated full-length ERRα protein, cell pellets of 600 ml culture 
were lysed in 100 ml lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM β-mercaptoethanol, 
100 mM KCl, 1% NP-40, 1:200 protease inhibitor cocktail III (Calbiochem, EMD 
Biosciences, Inc., San Diego, CA), 50 mM sodium fluoride, and 50 mM β-
glycerophosphate). The lysate was incubated at 4°C with gentle rocking for 1 hour, 
followed by centrifugation at 20,000 rpm for 30 min. 20% glycerol was added to the 
soluble fraction of the lysates for storage at -80°C. 
Before protein purification, the sample lysates was first run on a reducing SDS-
PAGE gel, transferred to a nitrocellulose membrane followed by detection with an anti-
ERRα (1148) antibody to confirm the production of biotinylated ERRα. Then, 
recombinant biotin-tagged-ERRα was purified from the soluble lysate using 
Streptavidin Mutein Matrix resin (Roche, Indianapolis, IN). The beads were packed in a 
5ml column and washed with water using “AKTA” FPLC (GE Healthcare Life Sciences). 
Cell lysate was filtered through a 0.45 μm filter and loaded onto the column at a flow 
rate of 5 ml/minute. The column was first equilibrated with 20 column volume (100 ml) 
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of Equilibration buffer (10 mM Tris-HCl, pH=8.0, 300 mM NaCl), then washed with 20 
column volume (100 ml) of Washing buffer (20 mM Tris-HCl, pH=8.0, 150 mM NaCl, 10 
mM β-mercaptoethanol, 10% glycerol), and finally eluted with 5 column volume (25 ml) 
of Elution buffer (50 mM Tris-HCl, pH 8.0, 200 mM NaCl, 4 mM DTT, 5 mM D-Biotin, 
10% glycerol) and collected into 6 separate fractions. To determine protein sample 
concentration, Bradford assay was used. To assess protein purity, protein samples were 
run on an SDS-PAGE gel followed by Coomassie staining. To determine the expression 
of biotin-tagged-ERRα, western blots were performed by transferring the proteins to a 
nitrocellulose membrane followed by detection with an anti-ERRα (1148) antibody. 
4.2.3 Functional Testing of Recombinant ERRα 
The functionality of the purified ERRα protein was assessed by two criteria (1) its 
DNA binding ability and (2) its ability to bind coactivators.  The latter was determined 
using an M13 phage (D30), which was shown previously to bind ERRα and expresses a 
short peptide, HPTHSSRLWELLMEATPTM, containing the coactivator:receptor 
interacting LXXLL motif. 
96-well plates were coated with 10 μg neutravidin (Pierce Biotechnology, 
Rockford, IL) in 100 μl of 100 mM NaHCO3 (pH 8.5) overnight at 4°C, blocked with 150 
μl of 2% milk in NaHCO3 for 1 hour at RT, washed five times with 300 μl PBST 
(Phosphate Buffered Saline with 1% Tween) and incubated for 1 hour with 100 μl of 2 
pmoles of biotinylated dsDNA containing an estrogen response element (ERE) sequence 
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(Forward: biotin- GATCTAGGTCACAGTGACCTGCG; Reverse: biotin-
GATCCGCAGGTCACTGTGACCTA). Extra biotin binding sites were blocked with 150 
μl of 5 mM biotin in PBS for 1 hour, and washed five times with 300 μl PBST. As a 
negative control, wells were coated with 10 μg milk instead of neutravidin and the 
incubation with biotinylated dsDNA and biotin was also replaced with PBS.  
0, 2, 5, 10 pmoles of purified biotinylated ERRα in PBST were added to the 
coated wells and incubated overnight at 4°C. Each well was blocked with 150 μl of 2% 
milk in PBST at RT for 1 hour, and then washed five times with PBST to remove 
unbound ERRα and milk. Meanwhile, M13-D30 phage was blocked with 2% milk in 
PBST on ice for 1 hour. Next, each well coated was incubated with 5x109 phage in 100 μl 
of 2% milk/PBST at RT for 1 hour, and washed five times with PBST to remove unbound 
phage. 
To detect the binding of M13-D30 phage to ERRα, each well was incubated with 
100 μl of the diluted horseradish peroxidase-conjugated anti-M13 antibody (1:5000 in 
PBST) (Pharmacia, catalog # 27-9402-01) at RT for 1 hour, washed ten times with PBST, 
and incubated with 100 μl of ABTS (29,29-azino-bis-3-ethylbenzthiazoline-6-sulfonic 
acid) reagent containing 0.05% H2O2.  The reaction was quantified by measuring the 
absorbance at 405 nm with a microtiter plate reader after 10 minutes. 
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4.2.4 M13 Phage Display 
To detect the conformations of ERRα with and without DNA binding, two 
different coating conditions were used. i) For DNA-bound ERRα detection, the coating 
of wells was similar to the method described above. In brief, 96-well plates (Costar, 
Corning, Acton, MA) were coated at RT with 10 μg neutravidin in 100 mM NaHCO3 (pH 
8.5) for 2 hours, blocked with 2% milk in NaHCO3 for 1 hour, washed five times with 
PBST, incubated with 10 pmoles of biotinylated dsDNA containing ERE for 1 hour, 
blocked with 5 mM biotin in PBS for 1 hour, and washed five times with PBST. Each 
well was incubated overnight at 4°C with 10 pmoles (520 ng) of biotinylated full‐length 
ERRα diluted in 100 μl PBST. To detect the conformations of ERRα in apo and ligand-
bound form, each well was supplemented with 0.1 μl DMSO, 0.1 μl of 10mM XCT-790, 
or 0.1 μl of 10 mM Compound A. ii) For non-DNA-bound ERRα detection, 96-well 
plates were directly coated with 10 pmoles ERRα in 100 μl of 100 mM NaHCO3 (pH 8.5) 
supplemented with 0.1 μl DMSO, 0.1 μl of 10 mM XCT-790, or 0.1 μl of 10 mM 
Compound A and incubated overnight at 4°C.  
The construction of the M13 phage library displaying LXXLL peptides was 
previously described (Chang, Norris et al. 1999). To pre-clear the phage library, 108 pfu 
phage from phage library were diluted with 150 μl of 2% milk in PBS and incubated on 
ice for 1 hour. Meanwhile, coated wells were blocked with 150 μl of 2% milk in PBS at 
RT for 1 hour, and washed five times with PBST. Pre-cleared phage were transferred to 
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the washed wells and incubated at RT for 3 hours (Panning). Wells were washed ten 
times with PBST to remove unbound phage. Finally, phage were eluted by adding 100 μl 
of 0.1 M HCl and incubated at RT for 10 minutes. Eluents were neutralized with 50 μl of 
1 M Tris-HCl (pH=7.4). Eluted phage were stored at 4°C until proceeded to 
amplification.  
To amplify the eluted phage, phage were mixed with E. coli DH5αF’ cells 
(Invitrogen, Carlsbad, CA) and incubated in 37°C shaker for 5 hours. Cells were spun 
down at 4000 g for 10 minutes, and the supernatant containing amplified phage was 
collected and stored at 4°C for subsequent rounds of panning. A total of five rounds of 
panning were conducted. 
4.2.5 Phage ELISA 
To confirm the enrichment of ERRα‐binding phage, a phage ELISA assay similar 
to the M13-D30 phage ELISA was used. The plates coating was as described above in the 
M13 Phage Display, with the addition of negative control wells, which were incubated 
with 520 ng powdered milk instead of ERRα protein in 100 μl of 100 mM NaHCO3 at 
4°C overnight. Wells were blocked with 150 μl of 2% milk in PBS at RT for 1 hour. Wells 
were washed five times with PBST followed by the addition of 5 x109 pfu pre-cleared 
phage (amplified from each panning) in 100 μl PBST and incubated at RT for 1 hour. 
Wells were washed five times with PBST to remove unbound phage.  
 98 
To detect the binding of phage to ERRα, each well was incubated with 100 μl of 
the diluted horseradish peroxidase-conjugated anti-M13 antibody (1:5000 in PBST) at RT 
for 1 hour, washed ten times with PBST, and incubated with 100 μl of ABTS reagent 
containing 0.05% H2O2.  Reaction was quantified by measuring the absorbance at 405 nm 
with a microtiter plate reader after 10 minutes of reaction. 
PCR amplification of the peptides was performed using amplified phage from 
bacterial supernatants that showed significant enrichment of phage binding in ELISA. 
The PCR products were purified using Qiagen PCR clean-up kit, digested with Xba I 
and Xho I and ligated into pM5.1 vector. The peptide sequences were deduced by DNA 
sequencing. The recombinant pM5.1_peptide constructs were used for mammalian two‐
hybrid analysis. 
4.2.6 Mammalian Two-Hybrid Assay 
Mammalian two‐hybrid analyses were performed in HepG2 cells and Hela cells, 
both of which were obtained from American Type Culture Collection (Manassas, VA) 
and maintained in a humidified 37°C incubator with 5% CO2. Cells were cultured in 
Minimal Essential Medium (MEM) (Invitrogen) supplemented with 10% fetal bovine 
serum (HyClone, Logan, UT), 0.1 mM non‐essential amino acids and 1 mM sodium 
pyruvate (Invitrogen). For cell transfection and mammalian two-hybrid assay, cells were 
switched to Basal Medium Eagle (BME) supplemented with 10% fetal bovine serum 
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(HyClone, Logan, UT), 2 mM L-Glutamine, 0.1 mM non‐essential amino acids and 1 mM 
sodium pyruvate (Invitrogen).  
For transient transfections, HepG2 cells were seeded in wells of 96‐well plates 24 
hours prior to transfection. On the day of transfection, the media was aspirated and cells 
were washed once with PBS. 600 ng of total plasmids (containing 200 ng pM5.1_peptide, 
200 ng VP16_ERRα, 180 ng 5xGal4-luciferase and 20 ng pCMV B-GAL) per triplicate 
samples in 96‐well were mixed with Lipofectin® in OptiMEM according to 
manufacturer’s protocol (Invitrogen). Cells in each well were transfected with 10 μl 
DNA-lipofectin mixture. 
All ligand stocks were dissolved in DMSO before use in cell culture, and cells 
were treated with 10 μM XCT-790, 10 μM Compound A, or equivalent amount of DMSO 
vehicle 1-2 hours post‐transfection. Cells were lysed 42‐48 hours after transfection and 
assayed for luciferase and β‐galactosidase activities as described (Norris, Paige et al. 
1999) using a Fusion™ Universal Microplate Analyzer (PerkinElmer). Results were 
presented as luciferase activity normalized with β-Gal for transfection efficiency ± 
standard error of the mean (SEM) per triplicate samples. Results presented were 
representative of three independent transfection experiments. 
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4.3 Results 
4.3.1 Purification of biologically active full-length ERRα 
To study the conformation of ERRα, we purified biologically active full-length 
protein of this receptor. ERRα was selected because of our interest in its role in breast 
cancer. It’s been described previously for other NRs that binding of ligands to the LBD 
can influence the orientation and/or activity of other domains of the same receptor. . 
Therefore, by using full-length ERRα for the peptide screen, it stands a better chance to 
identify global conformational differences between ERRα apo form and antagonist-
bound form. 
The expression system to produce full-length biologically active nuclear 
receptors in insect cells was previously described (Duffy, Tsao et al. 1998)). The ERRα 
cDNA with a canonical biotinylation sequence at the amino-terminus for the E. coli 
biotin holoenzyme synthetase (BirA) was cloned into a baculovirus expression vector 
and introduced into insect cells together with an expression vector for the BirA enzyme 
(Gaillard, Dwyer et al. 2007). The recombinant receptor was purified to homogeneity 
using Streptavidin Mutein Matrix resin column. Figure 4.1 shows a coomassie-stained 
SDS-PAGE gel of the steps of ERRα purification. A protein band between 50 kD and 75 
kD, which was the correct size for biotinylated ERRα was purified. It is shown by the 
coomassie stained gel that Elution 2 and Elution 3 appear to have highest protein level, 
and the purified protein has greater than 90% purity. Using Bradford protein assay, it 
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was determined that the protein concentration of Elution 2 and Elution 3 combined is 
about 480 ng/μl. 
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Figure 4.1 Purification of biotin-tagged full-length ERRα. 
Biotin-tagged full-length human ERRα was purified using a baculoviral 
expression system in Sf9 cells. Sf9 cells infected with baculovirus to express biotin-
tagged ERRα were lysed and samples were collected during multiple stages of the 
purification process and loaded into each well of a 10 % SDS-PAGE gel Coomassie 
staining. (1, Input; 2, blank lane; 3, flow through; 4, blank lane; 5, Wash 1; 6, Wash 2; 7, 
Wash 3; 8, Wash 4; 9, Elute 1; 10, Elute 2; 11, Elute 3; 12, Elute 4; 13, Elute 5; 14, Elute 6; 
15, Protein molecular Ladder) 
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4.3.2 Functional Verification of Recombinant ERRα 
To confirm the purified ERRα protein is folded correctly, its ability to bind 
coactivators was used as the main criterion to assess its biological activity. Peptide D30 
is a peptide (HPTHSSRLWELLMEATPTM) that contains a leucine-rich motif (LXXLL) 
frequently found within NR-interaction domains of coactivators and is known to bind 
ERRα (Gaillard, Dwyer et al. 2007). Thus, using a phage ELISA assay, we directly 
assessed the ability of the purified ERRα protein to bind M13-D30 peptide phage as a 
proxy of the biological activity of the purified ERRα protein.  
Figure 4.2 depicts the components of the phage ELISA assay. The neutravidin-
coated wells were first incubated with biotinylated double-stranded DNA that contains 
an estrogen response element (ERE) sequence, which is known to bind ERRα. Then, 
ERRα protein was incubated with the ERE. Following binding of the protein, M13-D30 
phage was added to the wells, and binding of the phage to the purified receptor was 
detected with an anti-M13-HRP antibody.  
Figure 4.3 shows the results of a representative ELISA assay, demonstrating that 
the purified ERRα was able to (1) bind ERE-containing DNA and (2) the D30 peptide. 
The ability of the purified ERRα to bind to the LXXLL motif of a coactivator confirms 
that the purified receptor is biologically active with respect to DNA binding and its 
ability to recruit coactivator proteins. 
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Figure 4.2 Diagram of the phage ELISA assay 
Phage ELISA assay was used to assess coactivator-binding capacity of the 
purified full-length recombinant ERRα. HRP: horseradish peroxidase; Bt-ERRα:  
biotinylated ERRα protein; Bt-ERE: biotinylated double-stranded DNA containing an 
estrogen response element (ERE). 
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Figure 4.3 Purified human ERRα is biologically active. 
The phage ELISA assay demonstrated that the purified ERRα is capable of 
binding to DNA and subsequently interacting with an LXXLL motif-containing peptide 
in vitro. Neutravidin-coated wells on 96-well plates were blocked with milk and 
incubated with biotinylated dsDNA containing ERE for 1 hour. Extra biotin binding 
sites were blocked with biotin for 1 hour. As a negative control, instead of neutravidin 
coating, biotinylated dsDNA incubation and biotin blocking, wells were coated with 
powdered milk. Next, 0, 2, 5, 10 pmoles of purified biotinylated ERRα were added to the 
coated wells and incubated overnight at 4°C. The wells were incubated with pre-cleared 
M13-D30 phage on ice for 1 hour, washed with PBST to remove unbound phage, and 
treated with horseradish peroxidase-conjugated anti-M13 antibody. The quantification 
of the bound antibody was performed by incubating wells with ABTS reagent and 
measuring the absorbance at 405 nm. 
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4.3.3 Identification of ERRα interacting peptides by M13 phage 
display 
Various methods have been used to probe the conformational changes induced 
upon ligand biding to NR.  One of the approaches that has been optimized by our lab is 
the M13 phage display, which has been used successfully in the past to search for 
peptide sequences that mimic endogenous protein-protein interactions.  To screen for 
small peptides that can interact with ERRα and serve as probes for the conformational 
changes of the receptor, an M13 phage library expressing 19 amino acid peptides 
(X)7LXXLL(X)7 on phage capsids were incubated with purified ERRα protein as apo, 
XCT-bound or Compound A-bound forms. The screen was conducted in two formats 
with ERRα either bound directly to the plastic or ERRα bound to an ERE because it is 
possible that the DNA binding of ERRα could influence its conformation. Therefore, 
combining screens performed under both conditions should increase the likelihood of 
detecting subtle conformational changes within receptor. After incubating phage library 
with ERRα in coated wells, unbound phage were washed off, while the phage bound to 
the receptor were eluted and amplified. The amplified phage was carried on to more 
rounds of binding, washing, elution, and amplification. This process known as 
“biopanning” is depicted in Figure 4.4. A total of five rounds of panning were 
conducted.  
In order to confirm the enrichment of ERRα-binding phage, a phage ELISA assay 
similar to that described earlier in the chapter was performed. Instead of a single 
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isolated phage, coated wells were incubated with amplified pools of phage from each 
pan. In our phage ELISA assay, six different conditions were tested to probe ERRα 
conformations with or without DNA binding, and in the presence of vehicle (DMSO), 
XCT, or Compound A. For conditions 1-3, the wells were first coated with neutravidin 
and biotinylated DNA containing ERE for ERRα binding, while conditions 4-6 used 
wells with ERRα bound directly to the plastic. For each condition, negative control wells 
incubated with milk instead of ERRα protein were used to indicate indicate whether the 
binding of phage was specific to the ERRα protein.  
Figure 4.5 is a representative phage ELISA showing the enrichment of phage for 
ERRα binding. For DNA-bound ERRα in the presence of Compound A (Condition 3), 
the phage binding was enriched from pan three through pan five, which is much slower 
than Apo-form ERRα (Condition 1). Comparing ERRα bound to DNA versus ERRα 
bound directly to plastic, the latter was enriched much slower, especially in the presence 
of Compound A (condition 6), where the phage binding was non-specific.  
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Figure 4.4 Workflow of peptide screen using M13 Phage Display. 
In the M13 phage display screen, a pool of M13 phage expressing 19-amino acid 
peptides containing LXXLL on their capsids are incubated in 96-well plate with the 
purified ERRα protein. Unbound phage clones are washed away, while phage bound to 
ERRα are eluted and amplified. During these rounds of “biopanning”, phage clones 
compete for ERRα binding and phage that bind with high affinity will be enriched. The 
enrichment of ERRα-binding phage is tested using phage ELISA assay. DNA sequencing 
is used to identify the sequence of each phage-expressed, and the binding of each 
individual phage peptide to ERRα can be confirmed in cells using a mammalian two 
hybrid assay.  
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Figure 4.5 Enrichment of ERRα - interacting phage 
A phage ELISA assay was performed to determine whether the biopanning 
enriched for phage that expressed peptides that bound to ERRα. Condition 1, 2, 3: wells 
were coated with neutravidin and biotinylated double-stranded DNA oligomers 
containing a canonical ERE. Throughout the process of plate coating, ERRα incubation, 
and phage binding, each of the three conditions was supplemented with vehicle 
(DMSO), XCT and Compound A, respectively.  Condition 4, 5, 6:  wells were coated 
directly with ERRα protein and the panning was performed in the presence of vehicle 
(DMSO), XCT and Compound A, respectively. To test the selectivity of phage binding to 
ERRα protein, negative control wells incubated with milk instead of ERRα protein were 
included for all the six coating conditions. The presence of phage was detected using an 
anti-M13-HRP-conjugated antibody and quantified by measuring the absorbance at 405 
nm upon the addition of a colorimetric HRP substrate ABTS. 
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4.3.4 Characterization of ERRα interacting peptides 
To confirm the ability of individual peptides to bind ERRα, their coding DNA 
fragments were subcloned into a pM5.1 vector creating a Gal4 DNA binding domain 
(Gal4DBD)-fusion protein for mammalian-two-hybrid assays (M2H). Interaction 
between the Gal4DBD-peptide fusion and the VP16- ERRα fusion activates the 
transcription of a luciferase reporter gene under the control of the Gal4-response 
element. After transformation of pM5.1_peptide plasmids into DH5α, 95 isolated clones 
were picked for DNA sequencing, which resulted in the identification of 24 unique 
peptide sequences. Further characterization by cell-based mammalian two-hybrid assays 
confirmed the interaction between ERRα and 22 of the 24 peptides. The list of these 
confirmed peptides is shown in Table 4.1. A representative mammalian-two hybrid 
result is shown in Figure 4.6. PGC1α_L3 is a peptide from the third LXXLL motif of 
PGC-1α, and was included as a positive control in this assay. VP16 vector instead of 
VP16-ERRα plasmid was used as a negative control, which demonstrated none of these 
peptides had intrinsic transcriptional capacity in the absence of ERRα receptor.  
As shown in Figure 4.6, peptides found to bind to ERRα fall into two categories 
based on the peptide-receptor interaction patterns. Some peptides interact with ERRα 
with decreased binding affinity in the presence of ERRα antagonist XCT or Compound 
A, while other peptides interact with ERRα and are not affected by ERRα antagonists. 
Surprisingly, none of the peptides selectively bind only one form of ERRα. 
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To pinpoint the ERRα surfaces available and important for peptide/protein 
interaction, peptides that interact with wild type ERRα were tested for binding to 
various ERRα mutants using a mammalian-two hybrid assay (Figure 4.7).  The deletion 
mutants deleN, deleLBD and deleH12 are ERRα mutant with deletions of the N-
terminus, the ligand binding domain (LBD) and the Helix 12 of the LBD, respectively. 
K244A/3x is a mutant with the following mutations K244A, K412N, E416Q and E419Q, 
and has been shown to abolish ERRα/PGC-1α interaction (Gaillard, Dwyer et al. 2007). 
Strikingly, all these mutations we tested can cause changes to the binding affinity of the 
peptide to the receptor. 
Since these peptides can interact with ERRα, overexpression of these peptides 
may interfere with receptor activity by competing with cofactors for ERRα binding. To 
test the potential utility of these peptides, a transactivation assay was used. HeLa cells 
were transfected with 3xERE-TATA-luciferase reporter, pcDNA_ERRα and 
pM5.1_peptide plasmid. pM5.1 empty vector was used as a negative control for the 
effect of the peptides to be tested. pM_PGC1αL3 and pM_L3_09 express two peptides 
known to interrupt ERRα/PGC-1α interaction and served as positive controls. As shown 
in Figure 4.8, several peptides (such as JL11, JL16 and JL20) decrease the transcriptional 
activity of ERRα, suggesting these small peptides can compete with endogenous ERRα 
cofactor, most likely PGC-1α in this case. However, other peptides (such as JL1 and JL8) 
did not affect the transcriptional activity of ERRα. One possible explanation is that these 
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peptides do not have high enough binding affinity to compete with endogenous ERRα 
cofactor(s). It is also possible that these peptides are binding to regions of the receptor 
not required for cofactor interaction. 
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Table 4.3: List of ERRα-interacting peptides identified by M13 phage display screen. 
JL1 - JL22 are 22 unique peptides that were identified by M13 phage display 
screen of ERRα, with the receptor either binding DNA or directly on the plastic. The 
interaction between these peptides and ERRα was confirmed in cell-based assays. 
 
 
 
 
Peptide Sequence 
JL1 DLTRYPVLWELLTQGSGAE 
JL2 TCVNYPLLCGLLNDRPIIT 
JL3 DVTQYPELLRLLLSMEQTD 
JL4 NCWEFPWLCGLLTQDRKTT 
JL5 DIARYPELMGLLLSNRPVV 
JL6 ELSDSWLLRQLLGQHPVNQ 
JL7 PPEKFPMLRGLLTDGVGNQ 
JL8 PAEGSWLLRCLLGQCEGGY 
JL9 SVDRWPELLRLLQPTEFSM 
JL10 GLTRYPVLWELLTQGSGAE 
JL11 MASDWPLLAALLNGGSPQM 
JL12 LPSGFPELFRLLTEPELQV 
JL13 HPEDFPLLRSLLSCESFEC 
JL14 PLENFPLLLSLLTSEGPEV 
JL15 GPSDFPILWNLLTTSVSGD 
JL16 NLDEWPILAALLQSPEGEL 
JL17 HSQDYPLLFSLLTKEHLAD 
JL18 PLTQGSWLERLLSTGVADA 
JL19 GVDDYPLLRALLLGQQQRG 
JL20 VPEAYPYLLELLSRDDLRL 
JL21 DMTGYPLLRGLLLQGMEPA 
JL22 DIARYPVLWELLTQGSGAE 
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Figure 4.6 Selected peptides interact with ERRα in a mammalian-two-hybrid assay 
A. Diagram of mammalian-two-hybrid assay used in (B). Interaction between a 
small peptide fused to a Gal4-DNA binding domain (Gal4DBD) and ERRα fused to 
VP16 activates the transcription of a luciferase reporter construct under the control of 
Gal4-response element. B. Mammalian two-hybrid assay assessing the ability of the 
indicated peptides to interact with ERRα. HepG2 cells in 96-well plates were transfected 
with 600 ng of total plasmids containing 180 ng 5xGal4-luciferase, 20 ng pCMV B-GAL, 
200 ng VP16_ERRα and 200 ng of indicated pM5.1_peptide per triplicate samples. 
PGC1α_L3 is a positive control peptide that contains the third LXXLL motif from PGC-
1α and is known to interact with ERRα. Cells were treated with 10 μM XCT-790, 10 μM 
Compound A, or equivalent amount of DMSO vehicle for 8 hours before harvest. Cells 
were lysed 24 or 48 hours after transfection and assayed for luciferase and β‐
galactosidase activities. Results are expressed as luciferase activity normalized with β-
Gal for transfection efficiency +/- standard error of the mean (SEM) per triplicate 
samples.  
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Figure 4.7 Interaction between selected peptides and ERRα mutants 
Interactions between small peptides fused to Gal4DBD and ERRα mutants fused 
to VP16 were assessed by mammalian-two-hybrid assay. HepG2 cells in 96-well plates 
were transfected with 600 ng of total plasmids containing 180 ng 5xGal4-luciferase, 20 ng 
pCMV B-GAL, 200 ng VP16_ERRα (or mutants) and 200 ng of indicated pM5.1_peptide 
per triplicate samples. Cells were treated with 10 μM XCT-790 (labeled as X), 10 μM 
Compound A (labeled as C), or equivalent amount of DMSO (labeled as D) vehicle for 8 
hours before harvest. Cells were lysed 48 hours after transfection and assayed for 
luciferase and β‐galactosidase activities. Results are expressed as luciferase activity 
normalized with β-Gal for transfection efficiency +/- standard error of the mean (SEM) 
per triplicate samples. 
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Figure 4.8 Selected peptides interfere with ERRα transcriptional activity 
The identified peptides were tested for their potential to disrupt ERRα activity in 
a transactivation assay. HeLa cells were transfected with 1000 ng 3xERE-TATA-
luciferase, 50 ng CMV β-Gal, either 10 ng ERRα or 10 ng pcDNA empty vector, and 
1000 ng of the indicated pM5.1_peptide plasmid. The total amount of plasmid DNA was 
normalized to a total of 3000 ng with pBSII. Results are expressed as luciferase activity 
normalized with β-Gal for transfection efficiency) +/- standard error of the mean (SEM) 
per triplicate sample of cells. 
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4.4 Discussion 
To our knowledge, this is the first time that ERRα antagonists have been used to 
probe for conformational differences in the full-length ERRα protein.   So far, 
crystallography studies have explored the structures of the ligand binding domains 
(LBD) of ERRα and ERRγ. Several available LBD crystal structures include ERRα LBD in 
complex with a PGC-1α peptide (PDB accession code 1XB7 and 3D24), ERRα LBD in 
complex with an inverse agonist cyclohexylmethyl-(1-p-tolyl-1H-indol-3-ylmethyl)-
amine (also known as compound 1a ; PDB accession code 2PJL), ERRγ LBD in complex 
with a SRC1 peptide (PDB accession code 1KV6 and 1TFC), and ERRγ LBD in complex 
with diethylstilbestrol or 4-hydroxytamoxifen (PDB accession code 1S9P and 1S9Q)  
(Greschik, Wurtz et al. 2002, Greschik, Flaig et al. 2004, Kallen, Schlaeppi et al. 2004, 
Kallen, Lattmann et al. 2007, Greschik, Althage et al. 2008). However, no structural 
information is available for full-length ERRα in either apo or antagonist-bound form. 
Here we utilized this phage display strategy to survey conformation of the full-length 
ERRα protein in Apo, XCT-bound and Compound A-bound states. 
The affinity of a given peptide for ERRα may be indicated by the number of 
times the clone is pulled out of the screen. The appearance frequency of a peptide in a 
screen can largely depend on its binding affinity, although phage with considerably 
higher amplification rate may also affect the screen result. Many peptide clones such as 
JL1 and JL8 were each pulled out of the screen multiple times. Our cell-based assays 
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confirmed that 22 out of the 24 peptides can interact with ERRα in cells, suggesting the 
effectiveness of our phage screen to identify ERRα-interacting peptides.  
The peptides identified in our screen include those which bind with higher 
affinity to apo ERRα than to antagonist bound ERRα, although the majority of the 
peptides are those that are unaffected by the presence of an ERRα antagonist. In fact, 
several peptides were each identified in multiple screen conditions. For example, 
peptide JL1 was recovered from ERRα + ERE + XCT, ERRα + ERE + Compound A, and 
ERRα + Compound A conditions.  Furthermore, mammalian two-hybrid assay (Figure 
4.6) demonstrated that the interactions between ERRα and many peptides including JL1 
were not affected by XCT or Compound A treatment indicating that these peptides bind 
to regions of ERRα that are available in apo ERRα and antagonist-bound forms. 
Given the LXXLL motif contained in the peptides, and the fact that ERRα 
deleLBD and K244A/3X mutants both abolished the binding of these peptides, it is 
highly likely that these peptides bind the AF2 coactivator binding pocket or nearby 
region of ERRα LBD. Using a random peptide library instead of the LXXLL peptide 
library for a future phage screen may have a better chance of identifying new regions on 
ERRα that can distinguish differently conformed receptor. Sequence alignment reveals 
that the peptides we identified have a consensus sequence with residues such as 
Tyrosine (Y) on position 5 and Phenylalanine (F) on position 6 of the small peptide. To 
understand how these peptides could bind ERRα, we modeled the binding of these 
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peptides using the crystal structure of the SRC1 peptide in complex with ERRγ as a 
scaffold. We found that, if the peptides bind ERRα on the same coactivator interaction 
surface as the SRC1 peptide, the Tyrosine on position 5 could form a hydrogen bond 
with a Glutamine in Helix 4 of ERRα, while the Leucine or Valine residue on position 7 
could pack nicely with a Leucine on Helix 12 of ERRα.  
One thing worth noticing is that some peptides showed different binding 
affinities to wild-type ERRα and deleN mutant. This suggests that the NH2-terminal of 
the receptor is also involved in the interaction. The interdomain interaction between the 
NH2-terminal and carboxyl-terminal (N/C interaction) has been reported for Androgen 
(Langley, Zhou et al. 1995, He and Wilson 2002), Estrogen (Kraus, McInerney et al. 1995), 
Progesterone (Tetel, Giangrande et al. 1999) and Mineralocorticoid receptors (Pippal, 
Yao et al. 2009). Although the NH2-terminal of ERRα receptor is much shorter compared 
to these other nuclear receptors, it is possible that these domains form a similar 
interaction in the ERRα protein. 
Not only could the peptides identified in these studies serve as conformational 
probes to assess how an antagonist modulates ERRα, the fact that some peptides can 
block the ERRα/PGC-1α interaction suggests that these peptides have the potential to 
selectively modulate ERRα activity. 
 121 
Conclusions and Implications 
Our study of ERRα covers both the functional definition and the molecular 
dissection of this receptor.  In this chapter, our findings will be summarized in the 
context of literature reports and discuss their implications for future research in this 
area. 
Functional definition of ERRα in breast cancer 
Over the past few years, a number of papers were published that examined the 
role of ERRα in breast cancer. The correlation between ERRα expression/activity and 
poor prognosis was established in breast cancer patients (Suzuki, Miki et al. 2004, 
Chang, Kazmin et al. 2011). Targeting ERRα also exhibited an inhibitory effect in breast 
tumor xenograft growth (Stein, Chang et al. 2008, Bianco, Lanvin et al. 2009, Chisamore, 
Cunningham et al. 2009). These findings inspired our exploration of ERRα function in 
breast cancer. Here, we sought to address the question of how ERRα promotes breast 
cancer growth and progression, the answer to which may potentially lead to the 
development of novel therapeutic targets. 
At the outset of this project, it was reported that breast cancer cells with ERRα 
knock-down did not show a difference in proliferative rate in vitro, while significantly 
retarded growth was observed when these cells were implanted as xenograft tumors 
(Stein, Chang et al. 2008). This finding forced us to consider the differences between in 
vitro culture versus a xenograft model. One striking difference is an increased metabolic 
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requirement and hypoxic stress of the tumor environment, both of which induce 
angiogenesis. In fact, several groups have shown that VEGF is a direct target gene of 
ERRα (Ao, Wang et al. 2008, Arany, Foo et al. 2008, Stein, Gaillard et al. 2009, 
Klimcakova, Chenard et al. 2012). Thus, we hypothesized that ERRα may be involved in 
breast cancer angiogenesis by induction of pro-angiogenic factors.   
A previous microarray study using the ERRα-selective PGC-1α coactivator 
surveyed the ERRα transcriptome in breast cancer cells.  In this study, we observed a 
dramatic induction of ECM1. Given its prospective role in angiogenesis, we focused on 
ECM1 as a potential target to understand the implication of ERRα regulation in 
angiogenesis. Our data clearly shows that (1) ECM1 is a target gene of ERRα; (2) ECM1 
has pro-angiogenic activity; and (3) ECM1 knockdown retarded tumor xenograft 
growth. These findings support our hypothesis that ERRα regulates pro-angiogenic 
genes to promote breast cancer growth. However, several questions remain to be 
determined to link the regulation of ECM1 by ERRα and the role of ERRα in tumor 
angiogenesis.  
One major question is:  how is ECM1 regulated by ERRα in tumor setting? The 
massive induction of ECM1 in our study was achieved using exogenous overexpression 
of PGC-1α to activate ERRα, yet the role of PGC-1α in cancer remains controversial. Our 
assumption is that, although not highly expressed in breast cancer cells, PGC-1α can be 
upregulated as a metabolic sensor in the tumor environment, and thus induces ECM1 
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expression. How robust this induction is as compared to our overexpression of PGC-1α 
remains to be examined. While this study used PGC-1α to activate ERRα, it has recently 
been shown that PGC-1β can be upregulated in breast cancer cells by activation of the 
Her2/IGF-1R signaling pathways and subsequent C-MYC stabilization (Chang, Kazmin 
et al. 2011). Thus, using PGC-1α alone to study the role of ERRα function in cancer may 
introduce bias in target gene searching. In fact, our preliminary studies suggested a 
similar induction of ECM1 by exogenous overexpression of PGC-1β. However, it is 
unclear whether this induction is biologically relevant. In our available cell models for 
breast cancer, MDA-MB-231 and MDA-MB-436 cells, there is high expression of ECM1, 
but these cells lack Her2 and thus cannot activate the Her2/IGF-1R signaling pathway. 
While MCF7 and SKBR3 cells are Her2 positive cells, they have very low basal 
expression of ECM1, and we did not observe ECM1 induction by of Her2/IGF-1R 
signaling activation in these cells. 
Another important question is to what extent does the pro-angiogenic effect of 
ECM1 account for the role of ERRα in breast tumor growth and angiogenesis. As we 
mentioned, VEGF expression can also be upregulated by ERRα, both through ERRα/ 
PGC-1α and ERRα/HIF signaling. While we observed ECM1 induction by ERRα/PGC-
1α, we did not see the effect of HIF stabilization on ECM1 expression. The relative 
contribution of ECM1 and VEGF in tumor angiogenesis remains to be tested.  
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Our preliminary in vitro studies suggested no synergistic effect from co-
treatment with recombinant VEGF and ECM1 on endothelial cell tube formation. This 
leads to another interesting question: what is the molecular mechanism of ECM1 
stimulated angiogenesis? We tested some known angiogenesis pathways that VEGF is 
involved in, such as Erk, Akt and p38. However, treating endothelial cells in vitro with 
recombinant ECM1 did not turn on these pathways. It has been reported that ECM1 
interacts with many extracellular matrix proteins, including perlecan, fibulin-1C/D, 
MMP-9, collagen type IV and laminin 332 (Mongiat, Fu et al. 2003, Fujimoto, Terlizzi et 
al. 2005, Fujimoto, Terlizzi et al. 2006, Sercu, Zhang et al. 2008, Sercu, Lambeir et al. 
2009). Thus, it is possible that the effect of ECM1 on endothelial cell tube formation is 
through its interacting components in the Matrigel, and the effect of knocking down 
ECM1 on tumor xenograft is through the alteration of extracellular matrix remodeling in 
the tumor microenvironment. This proposed mechanism remains to be tested.   
Molecular dissection of ERRα  
Dissecting the molecular mechanisms of ERRα function is another aspect of this 
research. Given the newly recognized ERRα activity on β-catenin and hypoxia-inducible 
factor-1 transcription, we focused on the mechanism of these non-canonical pathways 
regulated by ERRα. Unlike traditional transcriptional cofactors such as PGC-1, ERRα 
possesses a DNA Binding Domain that recognizes ERRE response element. Thus, we 
asked the question whether (1) DNA recognition is still required for ERRα activity, or (2) 
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ERRα is tethered to other transcriptional components via protein-protein interactions. 
Our preliminary data using ERRα DBD mutants in transcriptional reporter assays 
suggests the importance of an intact DNA binding domain for these non-canonical 
activities. However, our results do not definitively exclude (1) or (2), since the 
interactions between ERRα DBD mutants and β-cat or HIF-1 have not been tested. 
Nevertheless, the hypothesis that DNA recognition is still required for ERRα activity is 
currently preferred. Genomic bioinformatics studies suggested the existence of ERREs 
near TCF/LEF binding sites. Our transcriptional assay on a HIF reporter gene (HRE_luc) 
suggested a dampen effect of ERRα, which is contradictory to a previous report (Ao, 
Wang et al. 2008). This discrepancy may be due to the difference in reporter genes used, 
which suggests the minimum HRE element may be insufficient for ERRα activation.   
It has been recently shown that PGC-1α expression is induced under hypoxia 
conditions (Zhu, Wang et al. 2010). Thus, we asked the question of what is the role of 
PGC-1α on these HIF target genes under hypoxia conditions. When comparing the 
genes with enrichment of HIF binding sites and those regulated by ERRα coactivator 
PGC-1α overexpression in MCF-7 cells, we found many HIF target genes were 
downregulated by PGC-1α under normoxia. Future work to examine how ERRα 
coordinates between its canonical ERRα/ PGC-1α pathway and its non-canonical ERRα / 
HIF pathway will help in answering this question. 
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Despite the seemingly opposing effects of PGC-1α/ERRα and HIF-1 on some 
target genes, several target genes were identified to be regulated in the same direction 
by these two transcription factors. VEGF has been shown to be upregulated by both 
PGC-1α and HIF, and transient overexpression of PGC-1α under hypoxia has a 
synergistic effect with HIF activity. Similarly, we found that CA9, another HIF target 
gene, is downregulated by ERRα inhibition. Interestingly, overexpression of PGC-1α 
either under normoxia or hypoxia cannot upregulate CA9 expression. It is possible that 
in this context, the HIF-dependent and PGC-1α-independent effect of ERRα is mediated 
through its tethering to HIF. It is also possible that ERRα is acting through indirect 
mechanism on CA9. This question remains to be addressed.  
Finally, we surveyed the structure of full-length ERRα in Apo, XCT-bound and 
Compound A-bound forms using phage display and identified several peptides that 
interact with ERRα under these three conditions. Using ERRα mutants we concluded 
that the identified peptides bind in or near the AF2 coactivator binding pocket. 
However, some but not all peptides are discriminative in their binding of antagonist-
occupied ERRα. For future studies, using a random peptide library rather than the 
LXXLL peptide library for the phage screen may help in identify peptides that bind to 
other regions on ERRα. Not only could these peptides serve as conformational probes in 
assessing how antagonists impact the structure of ERRα, the discovery of small peptides 
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that block specific protein-protein interactions involving ERRα may have the potential to 
selectively modulate ERRα activity. 
In conclusion, we have explored various aspects of ERRα biology in this work. 
We identified a novel PGC-1α /ERRα target gene, ECM1, which is involved in breast 
tumor growth and angiogenesis. We proposed the potential mechanisms of ERRα non-
canonical pathways. Finally, we examined the effects ERRα antagonists have on ERRα 
structure. Our findings provide more insight into our understanding of ERRα function. 
However, these findings also leave many important questions unanswered and bring up 
new and unexplored aspects of ERRα biology. Future research to address these 
questions will further elucidate the role of ERRα in breast cancer, and thus lead to the 
development of novel therapeutic options for breast cancer patients. 
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